#' 20050181, figure 1A
#' 
#' Kaplan-Meier digitized data from 20050181, figure 1A (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer.
#' 
#' @source
#' Peeters M, Price TJ, Cervantes A, et al. Final results from a
#' randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line
#' treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:
#' 107–16.
#' 
#' @format
#' A data frame of 597 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr
#' }
#' 
#' @usage
#' X20050181_1A
#' 
#' @examples
#' summary(X20050181_1A)
#' 
#' kmplot(X20050181_1A)
"X20050181_1A"


#' 20050181, figure 1B
#' 
#' Kaplan-Meier digitized data from 20050181, figure 1B (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer.
#' 
#' @source
#' Peeters M, Price TJ, Cervantes A, et al. Final results from a
#' randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line
#' treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:
#' 107–16.
#' 
#' @format
#' A data frame of 486 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr
#' }
#' 
#' @usage
#' X20050181_1B
#' 
#' @examples
#' summary(X20050181_1B)
#' 
#' kmplot(X20050181_1B)
"X20050181_1B"


#' 20050181, figure 2A
#' 
#' Kaplan-Meier digitized data from 20050181, figure 2A (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer.
#' 
#' @source
#' Peeters M, Price TJ, Cervantes A, et al. Final results from a
#' randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line
#' treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:
#' 107–16.
#' 
#' @format
#' A data frame of 597 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr
#' }
#' 
#' @usage
#' X20050181_2A
#' 
#' @examples
#' summary(X20050181_2A)
#' 
#' kmplot(X20050181_2A)
"X20050181_2A"


#' 20050181, figure 2B
#' 
#' Kaplan-Meier digitized data from 20050181, figure 2B (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer.
#' 
#' @source
#' Peeters M, Price TJ, Cervantes A, et al. Final results from a
#' randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line
#' treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:
#' 107–16.
#' 
#' @format
#' A data frame of 486 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr
#' }
#' 
#' @usage
#' X20050181_2B
#' 
#' @examples
#' summary(X20050181_2B)
#' 
#' kmplot(X20050181_2B)
"X20050181_2B"


#' 2005B3030, figure 2A
#' 
#' Kaplan-Meier digitized data from 2005B3030, figure 2A (PMID 25515658). A reported sample size of 156 for a primary endpoint of DFS in lung cancer.
#' 
#' @source
#' Li N, Zeng Z-F, Wang S-Y, et al. Randomized phase III trial of
#' prophylactic cranial irradiation versus observation in patients with
#' fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk
#' of cerebral metastases after adjuvant chemotherapy. Ann Oncol 2015;
#' 26: 504–9.
#' 
#' @format
#' A data frame of 156 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, pci) \cr
#' }
#' 
#' @usage
#' X2005B3030_2A
#' 
#' @examples
#' summary(X2005B3030_2A)
#' 
#' kmplot(X2005B3030_2A)
"X2005B3030_2A"


#' 2005B3030, figure 2B
#' 
#' Kaplan-Meier digitized data from 2005B3030, figure 2B (PMID 25515658). A reported sample size of 156 for a primary endpoint of DFS in lung cancer.
#' 
#' @source
#' Li N, Zeng Z-F, Wang S-Y, et al. Randomized phase III trial of
#' prophylactic cranial irradiation versus observation in patients with
#' fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk
#' of cerebral metastases after adjuvant chemotherapy. Ann Oncol 2015;
#' 26: 504–9.
#' 
#' @format
#' A data frame of 156 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, pci) \cr
#' }
#' 
#' @usage
#' X2005B3030_2B
#' 
#' @examples
#' summary(X2005B3030_2B)
#' 
#' kmplot(X2005B3030_2B)
"X2005B3030_2B"


#' ACT1, figure 2A
#' 
#' Kaplan-Meier digitized data from ACT1, figure 2A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of
#' amrubicin versus topotecan as second-line treatment for patients with
#' small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
#' 
#' @format
#' A data frame of 637 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (amrubicin, topotecan) \cr
#' }
#' 
#' @usage
#' ACT1_2A
#' 
#' @examples
#' summary(ACT1_2A)
#' 
#' kmplot(ACT1_2A)
"ACT1_2A"


#' ACT1, figure 3A
#' 
#' Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of
#' amrubicin versus topotecan as second-line treatment for patients with
#' small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
#' 
#' @format
#' A data frame of 637 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (amrubicin, topotecan) \cr
#' }
#' 
#' @usage
#' ACT1_3A
#' 
#' @examples
#' summary(ACT1_3A)
#' 
#' kmplot(ACT1_3A)
"ACT1_3A"


#' ACT2, figure 2A
#' 
#' Kaplan-Meier digitized data from ACT2, figure 2A (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer.
#' 
#' @source
#' Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of
#' KRAS-guided maintenance therapy with bevacizumab, erlotinib or
#' metronomic capecitabine after first-line induction treatment of
#' metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016;
#' 27: 140–7.
#' 
#' @format
#' A data frame of 71 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (wt_b, wt_be) \cr
#' }
#' 
#' @usage
#' ACT2_2A
#' 
#' @examples
#' summary(ACT2_2A)
#' 
#' kmplot(ACT2_2A)
"ACT2_2A"


#' ACT2, figure 2B
#' 
#' Kaplan-Meier digitized data from ACT2, figure 2B (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer.
#' 
#' @source
#' Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of
#' KRAS-guided maintenance therapy with bevacizumab, erlotinib or
#' metronomic capecitabine after first-line induction treatment of
#' metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016;
#' 27: 140–7.
#' 
#' @format
#' A data frame of 67 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mut_b, mut_c) \cr
#' }
#' 
#' @usage
#' ACT2_2B
#' 
#' @examples
#' summary(ACT2_2B)
#' 
#' kmplot(ACT2_2B)
"ACT2_2B"


#' ACT2, figure 2C
#' 
#' Kaplan-Meier digitized data from ACT2, figure 2C (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer.
#' 
#' @source
#' Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of
#' KRAS-guided maintenance therapy with bevacizumab, erlotinib or
#' metronomic capecitabine after first-line induction treatment of
#' metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016;
#' 27: 140–7.
#' 
#' @format
#' A data frame of 71 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (wt_b, wt_be) \cr
#' }
#' 
#' @usage
#' ACT2_2C
#' 
#' @examples
#' summary(ACT2_2C)
#' 
#' kmplot(ACT2_2C)
"ACT2_2C"


#' ACT2, figure 2D
#' 
#' Kaplan-Meier digitized data from ACT2, figure 2D (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer.
#' 
#' @source
#' Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of
#' KRAS-guided maintenance therapy with bevacizumab, erlotinib or
#' metronomic capecitabine after first-line induction treatment of
#' metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016;
#' 27: 140–7.
#' 
#' @format
#' A data frame of 67 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mut_b, mut_c) \cr
#' }
#' 
#' @usage
#' ACT2_2D
#' 
#' @examples
#' summary(ACT2_2D)
#' 
#' kmplot(ACT2_2D)
"ACT2_2D"


#' ACTSCC, figure 2A
#' 
#' Kaplan-Meier digitized data from ACTSCC, figure 2A (PMID 24942277). A reported sample size of 1,518 for a primary endpoint of DFS_3yr in colorectal cancer.
#' 
#' @source
#' Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy
#' for stage III colon cancer: a randomized phase III study (ACTS-CC
#' trial). Ann Oncol 2014; 25: 1743–9.
#' 
#' @format
#' A data frame of 1,518 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (s_1, uft_lv) \cr
#' }
#' 
#' @usage
#' ACTSCC_2A
#' 
#' @examples
#' summary(ACTSCC_2A)
#' 
#' kmplot(ACTSCC_2A)
"ACTSCC_2A"


#' AIO0207(a), figure 3B
#' 
#' Kaplan-Meier digitized data from AIO0207(a), figure 3B (PMID 26361971). A reported sample size of 472 for a primary endpoint of time_tx_failure in colorectal cancer.
#' 
#' @source
#' Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance
#' strategies after first-line oxaliplatin plus fluoropyrimidine plus
#' bevacizumab for patients with metastatic colorectal cancer (AIO
#' 0207): a randomised, non-inferiority, open-label, phase 3 trial.
#' Lancet Oncol 2015; 16: 1355–69.
#' 
#' @format
#' A data frame of 301 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu_bev, no_tx) \cr
#' }
#' 
#' @usage
#' `AIO0207(a)_3B`
#' 
#' @examples
#' summary(`AIO0207(a)_3B`)
#' 
#' kmplot(`AIO0207(a)_3B`)
"AIO0207(a)_3B"


#' AIO0207(a), figure 3C
#' 
#' Kaplan-Meier digitized data from AIO0207(a), figure 3C (PMID 26361971). A reported sample size of 472 for a primary endpoint of time_tx_failure in colorectal cancer.
#' 
#' @source
#' Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance
#' strategies after first-line oxaliplatin plus fluoropyrimidine plus
#' bevacizumab for patients with metastatic colorectal cancer (AIO
#' 0207): a randomised, non-inferiority, open-label, phase 3 trial.
#' Lancet Oncol 2015; 16: 1355–69.
#' 
#' @format
#' A data frame of 314 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu_bev, no_tx) \cr
#' }
#' 
#' @usage
#' `AIO0207(a)_3C`
#' 
#' @examples
#' summary(`AIO0207(a)_3C`)
#' 
#' kmplot(`AIO0207(a)_3C`)
"AIO0207(a)_3C"


#' AIO0207(b), figure 3B
#' 
#' Kaplan-Meier digitized data from AIO0207(b), figure 3B (PMID 26361971). A reported sample size of 472 for a primary endpoint of time_tx_failure in colorectal cancer.
#' 
#' @source
#' Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance
#' strategies after first-line oxaliplatin plus fluoropyrimidine plus
#' bevacizumab for patients with metastatic colorectal cancer (AIO
#' 0207): a randomised, non-inferiority, open-label, phase 3 trial.
#' Lancet Oncol 2015; 16: 1355–69.
#' 
#' @format
#' A data frame of 300 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu_bev, bev) \cr
#' }
#' 
#' @usage
#' `AIO0207(b)_3B`
#' 
#' @examples
#' summary(`AIO0207(b)_3B`)
#' 
#' kmplot(`AIO0207(b)_3B`)
"AIO0207(b)_3B"


#' AIO0207(b), figure 3C
#' 
#' Kaplan-Meier digitized data from AIO0207(b), figure 3C (PMID 26361971). A reported sample size of 472 for a primary endpoint of time_tx_failure in colorectal cancer.
#' 
#' @source
#' Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance
#' strategies after first-line oxaliplatin plus fluoropyrimidine plus
#' bevacizumab for patients with metastatic colorectal cancer (AIO
#' 0207): a randomised, non-inferiority, open-label, phase 3 trial.
#' Lancet Oncol 2015; 16: 1355–69.
#' 
#' @format
#' A data frame of 312 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu_bev, bev) \cr
#' }
#' 
#' @usage
#' `AIO0207(b)_3C`
#' 
#' @examples
#' summary(`AIO0207(b)_3C`)
#' 
#' kmplot(`AIO0207(b)_3C`)
"AIO0207(b)_3C"


#' ALTTO(a), figure 2A
#' 
#' Kaplan-Meier digitized data from ALTTO(a), figure 2A (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,190 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l_t, t) \cr
#' }
#' 
#' @usage
#' `ALTTO(a)_2A`
#' 
#' @examples
#' summary(`ALTTO(a)_2A`)
#' 
#' kmplot(`ALTTO(a)_2A`)
"ALTTO(a)_2A"


#' ALTTO(a), figure 2B
#' 
#' Kaplan-Meier digitized data from ALTTO(a), figure 2B (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,190 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l_t, t) \cr
#' }
#' 
#' @usage
#' `ALTTO(a)_2B`
#' 
#' @examples
#' summary(`ALTTO(a)_2B`)
#' 
#' kmplot(`ALTTO(a)_2B`)
"ALTTO(a)_2B"


#' ALTTO(b), figure 2A
#' 
#' Kaplan-Meier digitized data from ALTTO(b), figure 2A (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,188 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (t, t_then_l) \cr
#' }
#' 
#' @usage
#' `ALTTO(b)_2A`
#' 
#' @examples
#' summary(`ALTTO(b)_2A`)
#' 
#' kmplot(`ALTTO(b)_2A`)
"ALTTO(b)_2A"


#' ALTTO(b), figure 2B
#' 
#' Kaplan-Meier digitized data from ALTTO(b), figure 2B (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,188 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (t, t_then_l) \cr
#' }
#' 
#' @usage
#' `ALTTO(b)_2B`
#' 
#' @examples
#' summary(`ALTTO(b)_2B`)
#' 
#' kmplot(`ALTTO(b)_2B`)
"ALTTO(b)_2B"


#' ALTTO(c), figure 2A
#' 
#' Kaplan-Meier digitized data from ALTTO(c), figure 2A (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,197 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, t) \cr
#' }
#' 
#' @usage
#' `ALTTO(c)_2A`
#' 
#' @examples
#' summary(`ALTTO(c)_2A`)
#' 
#' kmplot(`ALTTO(c)_2A`)
"ALTTO(c)_2A"


#' ALTTO(c), figure 2B
#' 
#' Kaplan-Meier digitized data from ALTTO(c), figure 2B (PMID 26598744). A reported sample size of 8,381 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant Lapatinib and
#' Trastuzumab for Early Human Epidermal Growth Factor Receptor
#' 2-Positive Breast Cancer: Results From the Randomized Phase III
#' Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J
#' Clin Oncol 2016; 34: 1034–42.
#' 
#' @format
#' A data frame of 4,197 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, t) \cr
#' }
#' 
#' @usage
#' `ALTTO(c)_2B`
#' 
#' @examples
#' summary(`ALTTO(c)_2B`)
#' 
#' kmplot(`ALTTO(c)_2B`)
"ALTTO(c)_2B"


#' AMAROS, figure 2A
#' 
#' Kaplan-Meier digitized data from AMAROS, figure 2A (PMID 25439688). A reported sample size of 4,823 for a primary endpoint of AxRecurrence-5yr in breast cancer.
#' 
#' @source
#' Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery
#' of the axilla after a positive sentinel node in breast cancer (EORTC
#' 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3
#' non-inferiority trial. Lancet Oncol 2014; 15: 1303–10.
#' 
#' @format
#' A data frame of 1,425 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (dissection, radiotherapy) \cr
#' }
#' 
#' @usage
#' AMAROS_2A
#' 
#' @examples
#' summary(AMAROS_2A)
#' 
#' kmplot(AMAROS_2A)
"AMAROS_2A"


#' AMAROS, figure 2B
#' 
#' Kaplan-Meier digitized data from AMAROS, figure 2B (PMID 25439688). A reported sample size of 4,823 for a primary endpoint of AxRecurrence-5yr in breast cancer.
#' 
#' @source
#' Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery
#' of the axilla after a positive sentinel node in breast cancer (EORTC
#' 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3
#' non-inferiority trial. Lancet Oncol 2014; 15: 1303–10.
#' 
#' @format
#' A data frame of 1,425 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (dissection, radiotherapy) \cr
#' }
#' 
#' @usage
#' AMAROS_2B
#' 
#' @examples
#' summary(AMAROS_2B)
#' 
#' kmplot(AMAROS_2B)
"AMAROS_2B"


#' ASPECCT, figure 2A
#' 
#' Kaplan-Meier digitized data from ASPECCT, figure 2A (PMID 24739896). A reported sample size of 1,010 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in
#' patients with chemotherapy-refractory wild-type KRAS exon 2
#' metastatic colorectal cancer (ASPECCT): a randomised, multicentre,
#' open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15:
#' 569–79.
#' 
#' @format
#' A data frame of 999 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cetuximab, panitumumab) \cr
#' }
#' 
#' @usage
#' ASPECCT_2A
#' 
#' @examples
#' summary(ASPECCT_2A)
#' 
#' kmplot(ASPECCT_2A)
"ASPECCT_2A"


#' ASPECCT, figure 3A
#' 
#' Kaplan-Meier digitized data from ASPECCT, figure 3A (PMID 24739896). A reported sample size of 1,010 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in
#' patients with chemotherapy-refractory wild-type KRAS exon 2
#' metastatic colorectal cancer (ASPECCT): a randomised, multicentre,
#' open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15:
#' 569–79.
#' 
#' @format
#' A data frame of 999 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cetuximab, panitumumab) \cr
#' }
#' 
#' @usage
#' ASPECCT_3A
#' 
#' @examples
#' summary(ASPECCT_3A)
#' 
#' kmplot(ASPECCT_3A)
"ASPECCT_3A"


#' ATTENTION, figure 2A
#' 
#' Kaplan-Meier digitized data from ATTENTION, figure 2A (PMID 26153496). A reported sample size of 460 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Yoshioka H, Azuma K, Yamamoto N, et al. A randomized, double-blind,
#' placebo-controlled, phase III trial of erlotinib with or without a
#' c-Met inhibitor tivantinib (ARQ 197) in Asian patients with
#' previously treated stage IIIB/IV nonsquamous nonsmall-cell lung
#' cancer harboring wild-type epidermal growth factor receptor
#' (ATTENTION study). Ann Oncol 2015; 26: 2066–72.
#' 
#' @format
#' A data frame of 307 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tivantinib) \cr
#' }
#' 
#' @usage
#' ATTENTION_2A
#' 
#' @examples
#' summary(ATTENTION_2A)
#' 
#' kmplot(ATTENTION_2A)
"ATTENTION_2A"


#' ATTENTION, figure 2B
#' 
#' Kaplan-Meier digitized data from ATTENTION, figure 2B (PMID 26153496). A reported sample size of 460 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Yoshioka H, Azuma K, Yamamoto N, et al. A randomized, double-blind,
#' placebo-controlled, phase III trial of erlotinib with or without a
#' c-Met inhibitor tivantinib (ARQ 197) in Asian patients with
#' previously treated stage IIIB/IV nonsquamous nonsmall-cell lung
#' cancer harboring wild-type epidermal growth factor receptor
#' (ATTENTION study). Ann Oncol 2015; 26: 2066–72.
#' 
#' @format
#' A data frame of 307 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tivantinib) \cr
#' }
#' 
#' @usage
#' ATTENTION_2B
#' 
#' @examples
#' summary(ATTENTION_2B)
#' 
#' kmplot(ATTENTION_2B)
"ATTENTION_2B"


#' AURA3, figure 1A
#' 
#' Kaplan-Meier digitized data from AURA3, figure 1A (PMID 27959700). A reported sample size of 419 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in
#' EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376: 629–40.
#' 
#' @format
#' A data frame of 419 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (osimertinib, platinum-pemetrexed) \cr
#' }
#' 
#' @usage
#' AURA3_1A
#' 
#' @examples
#' summary(AURA3_1A)
#' 
#' kmplot(AURA3_1A)
"AURA3_1A"


#' AZURE, figure 2A
#' 
#' Kaplan-Meier digitized data from AZURE, figure 2A (PMID 25035292). A reported sample size of 3,360 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in
#' patients with early breast cancer: final efficacy analysis of the
#' AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol
#' 2014; 15: 997–1006.
#' 
#' @format
#' A data frame of 3,359 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, zoledronic_acid) \cr
#' }
#' 
#' @usage
#' AZURE_2A
#' 
#' @examples
#' summary(AZURE_2A)
#' 
#' kmplot(AZURE_2A)
"AZURE_2A"


#' AZURE, figure 4
#' 
#' Kaplan-Meier digitized data from AZURE, figure 4 (PMID 25035292). A reported sample size of 3,360 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in
#' patients with early breast cancer: final efficacy analysis of the
#' AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol
#' 2014; 15: 997–1006.
#' 
#' @format
#' A data frame of 3,359 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, zoledronic_acid) \cr
#' }
#' 
#' @usage
#' AZURE_4
#' 
#' @examples
#' summary(AZURE_4)
#' 
#' kmplot(AZURE_4)
"AZURE_4"


#' BEACON, figure 2A
#' 
#' Kaplan-Meier digitized data from BEACON, figure 2A (PMID 26482278). A reported sample size of 852 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Perez EA, Awada A, O’Shaughnessy J, et al. Etirinotecan pegol
#' (NKTR-102) versus treatment of physician’s choice in women with
#' advanced breast cancer previously treated with an anthracycline, a
#' taxane, and capecitabine (BEACON): a randomised, open-label,
#' multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1556–68.
#' 
#' @format
#' A data frame of 852 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, etirinotecan_pegol) \cr
#' }
#' 
#' @usage
#' BEACON_2A
#' 
#' @examples
#' summary(BEACON_2A)
#' 
#' kmplot(BEACON_2A)
"BEACON_2A"


#' BEACON, figure 2B
#' 
#' Kaplan-Meier digitized data from BEACON, figure 2B (PMID 26482278). A reported sample size of 852 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Perez EA, Awada A, O’Shaughnessy J, et al. Etirinotecan pegol
#' (NKTR-102) versus treatment of physician’s choice in women with
#' advanced breast cancer previously treated with an anthracycline, a
#' taxane, and capecitabine (BEACON): a randomised, open-label,
#' multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1556–68.
#' 
#' @format
#' A data frame of 852 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, etirinotecan_pegol) \cr
#' }
#' 
#' @usage
#' BEACON_2B
#' 
#' @examples
#' summary(BEACON_2B)
#' 
#' kmplot(BEACON_2B)
"BEACON_2B"


#' BEBYP, figure 1
#' 
#' Kaplan-Meier digitized data from BEBYP, figure 1 (PMID 25600568). A reported sample size of 185 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of
#' bevacizumab beyond progression to first-line therapy in metastatic
#' colorectal cancer: final results of the randomized BEBYP trial. Ann
#' Oncol 2015; 26: 724–30.
#' 
#' @format
#' A data frame of 184 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_ct, ct) \cr
#' }
#' 
#' @usage
#' BEBYP_1
#' 
#' @examples
#' summary(BEBYP_1)
#' 
#' kmplot(BEBYP_1)
"BEBYP_1"


#' BEBYP, figure 3
#' 
#' Kaplan-Meier digitized data from BEBYP, figure 3 (PMID 25600568). A reported sample size of 185 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of
#' bevacizumab beyond progression to first-line therapy in metastatic
#' colorectal cancer: final results of the randomized BEBYP trial. Ann
#' Oncol 2015; 26: 724–30.
#' 
#' @format
#' A data frame of 184 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_ct, ct) \cr
#' }
#' 
#' @usage
#' BEBYP_3
#' 
#' @examples
#' summary(BEBYP_3)
#' 
#' kmplot(BEBYP_3)
"BEBYP_3"


#' BEYOND, figure 2A
#' 
#' Kaplan-Meier digitized data from BEYOND, figure 2A (PMID 26014294). A reported sample size of 276 for a primary endpoint of PFS in prostate cancer.
#' 
#' @source
#' Zhou C, Wu Y-L, Chen G, et al. BEYOND: A Randomized, Double-Blind,
#' Placebo-Controlled, Multicenter, Phase III Study of First-Line
#' Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese
#' Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung
#' Cancer. J Clin Oncol 2015; 33: 2197–204.
#' 
#' @format
#' A data frame of 276 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_cp, placebo_cp) \cr
#' }
#' 
#' @usage
#' BEYOND_2A
#' 
#' @examples
#' summary(BEYOND_2A)
#' 
#' kmplot(BEYOND_2A)
"BEYOND_2A"


#' BEYOND, figure 3A
#' 
#' Kaplan-Meier digitized data from BEYOND, figure 3A (PMID 26014294). A reported sample size of 276 for a primary endpoint of PFS in prostate cancer.
#' 
#' @source
#' Zhou C, Wu Y-L, Chen G, et al. BEYOND: A Randomized, Double-Blind,
#' Placebo-Controlled, Multicenter, Phase III Study of First-Line
#' Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese
#' Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung
#' Cancer. J Clin Oncol 2015; 33: 2197–204.
#' 
#' @format
#' A data frame of 276 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_cp, placebo_cp) \cr
#' }
#' 
#' @usage
#' BEYOND_3A
#' 
#' @examples
#' summary(BEYOND_3A)
#' 
#' kmplot(BEYOND_3A)
"BEYOND_3A"


#' BOLERO1, figure 2B
#' 
#' Kaplan-Meier digitized data from BOLERO1, figure 2B (PMID 26092818). A reported sample size of 719 for a primary endpoint of PFS(overall & HR- population) in breast cancer.
#' 
#' @source
#' Hurvitz SA, Andre F, Jiang Z, et al. Combination of everolimus with
#' trastuzumab plus paclitaxel as first-line treatment for patients with
#' HER2-positive advanced breast cancer (BOLERO-1): a phase 3,
#' randomised, double-blind, multicentre trial. Lancet Oncol 2015; 16:
#' 816–29.
#' 
#' @format
#' A data frame of 719 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (everolimus, placebo) \cr
#' }
#' 
#' @usage
#' BOLERO1_2B
#' 
#' @examples
#' summary(BOLERO1_2B)
#' 
#' kmplot(BOLERO1_2B)
"BOLERO1_2B"


#' BOLERO2, figure 1
#' 
#' Kaplan-Meier digitized data from BOLERO2, figure 1 (PMID 25231953). A reported sample size of 720 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus
#' exemestane for hormone-receptor-positive, human epidermal growth
#' factor receptor-2-negative advanced breast cancer: overall survival
#' results from BOLERO-2†. Ann Oncol 2014; 25: 2357–62.
#' 
#' @format
#' A data frame of 724 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (eve_exe, pbo_exe) \cr
#' }
#' 
#' @usage
#' BOLERO2_1
#' 
#' @examples
#' summary(BOLERO2_1)
#' 
#' kmplot(BOLERO2_1)
"BOLERO2_1"


#' BOLERO3, figure 2
#' 
#' Kaplan-Meier digitized data from BOLERO3, figure 2 (PMID 24742739). A reported sample size of 569 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with
#' trastuzumab-resistant, HER2-positive, advanced breast cancer
#' (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3
#' trial. Lancet Oncol 2014; 15: 580–91.
#' 
#' @format
#' A data frame of 569 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in weeks) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (eve_exe, placebo) \cr
#' }
#' 
#' @usage
#' BOLERO3_2
#' 
#' @examples
#' summary(BOLERO3_2)
#' 
#' kmplot(BOLERO3_2)
"BOLERO3_2"


#' BREC, figure 2A
#' 
#' Kaplan-Meier digitized data from BREC, figure 2A (PMID 25164908). A reported sample size of 279 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Moran T, Wei J, Cobo M, et al. Two biomarker-directed randomized
#' trials in European and Chinese patients with nonsmall-cell lung
#' cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann
#' Oncol 2014; 25: 2147–55.
#' 
#' @format
#' A data frame of 277 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, experimental) \cr
#' }
#' 
#' @usage
#' BREC_2A
#' 
#' @examples
#' summary(BREC_2A)
#' 
#' kmplot(BREC_2A)
"BREC_2A"


#' BREC, figure 2C
#' 
#' Kaplan-Meier digitized data from BREC, figure 2C (PMID 25164908). A reported sample size of 279 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Moran T, Wei J, Cobo M, et al. Two biomarker-directed randomized
#' trials in European and Chinese patients with nonsmall-cell lung
#' cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann
#' Oncol 2014; 25: 2147–55.
#' 
#' @format
#' A data frame of 124 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, experimental) \cr
#' }
#' 
#' @usage
#' BREC_2C
#' 
#' @examples
#' summary(BREC_2C)
#' 
#' kmplot(BREC_2C)
"BREC_2C"


#' CA097375, figure 2
#' 
#' Kaplan-Meier digitized data from CA097375, figure 2 (PMID 25794890). A reported sample size of 740 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Love RR, Laudico AV, Van Dinh N, et al. Timing of adjuvant surgical
#' oophorectomy in the menstrual cycle and disease-free and overall
#' survival in premenopausal women with operable breast cancer. J Natl
#' Cancer Inst 2015; 107: djv064.
#' 
#' @format
#' A data frame of 499 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (a, b) \cr
#' }
#' 
#' @usage
#' CA097375_2
#' 
#' @examples
#' summary(CA097375_2)
#' 
#' kmplot(CA097375_2)
"CA097375_2"


#' CA097375, figure 3
#' 
#' Kaplan-Meier digitized data from CA097375, figure 3 (PMID 25794890). A reported sample size of 740 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Love RR, Laudico AV, Van Dinh N, et al. Timing of adjuvant surgical
#' oophorectomy in the menstrual cycle and disease-free and overall
#' survival in premenopausal women with operable breast cancer. J Natl
#' Cancer Inst 2015; 107: djv064.
#' 
#' @format
#' A data frame of 499 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (a, b) \cr
#' }
#' 
#' @usage
#' CA097375_3
#' 
#' @examples
#' summary(CA097375_3)
#' 
#' kmplot(CA097375_3)
"CA097375_3"


#' CA184-095, figure 2A
#' 
#' Kaplan-Meier digitized data from CA184-095, figure 2A (PMID 28034081). A reported sample size of 602 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase
#' III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally
#' Symptomatic Patients With Metastatic Chemotherapy-Naive
#' Castration-Resistant Prostate Cancer. J Clin Oncol 2017; 35: 40–7.
#' 
#' @format
#' A data frame of 602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ipilimumab, placebo) \cr
#' }
#' 
#' @usage
#' `CA184-095_2A`
#' 
#' @examples
#' summary(`CA184-095_2A`)
#' 
#' kmplot(`CA184-095_2A`)
"CA184-095_2A"


#' CA184-095, figure 3
#' 
#' Kaplan-Meier digitized data from CA184-095, figure 3 (PMID 28034081). A reported sample size of 602 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase
#' III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally
#' Symptomatic Patients With Metastatic Chemotherapy-Naive
#' Castration-Resistant Prostate Cancer. J Clin Oncol 2017; 35: 40–7.
#' 
#' @format
#' A data frame of 602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ipilimumab, placebo) \cr
#' }
#' 
#' @usage
#' `CA184-095_3`
#' 
#' @examples
#' summary(`CA184-095_3`)
#' 
#' kmplot(`CA184-095_3`)
"CA184-095_3"


#' CA184043, figure 2A
#' 
#' Kaplan-Meier digitized data from CA184043, figure 2A (PMID 24831977). A reported sample size of 799 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after
#' radiotherapy in patients with metastatic castration-resistant
#' prostate cancer that had progressed after docetaxel chemotherapy
#' (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
#' Lancet Oncol 2014; 15: 700–12.
#' 
#' @format
#' A data frame of 799 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ipilimumab, placebo) \cr
#' }
#' 
#' @usage
#' CA184043_2A
#' 
#' @examples
#' summary(CA184043_2A)
#' 
#' kmplot(CA184043_2A)
"CA184043_2A"


#' CA184043, figure 4
#' 
#' Kaplan-Meier digitized data from CA184043, figure 4 (PMID 24831977). A reported sample size of 799 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after
#' radiotherapy in patients with metastatic castration-resistant
#' prostate cancer that had progressed after docetaxel chemotherapy
#' (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
#' Lancet Oncol 2014; 15: 700–12.
#' 
#' @format
#' A data frame of 799 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ipilimumab, placebo) \cr
#' }
#' 
#' @usage
#' CA184043_4
#' 
#' @examples
#' summary(CA184043_4)
#' 
#' kmplot(CA184043_4)
"CA184043_4"


#' CAIRO3, figure 2A
#' 
#' Kaplan-Meier digitized data from CAIRO3, figure 2A (PMID 25862517). A reported sample size of 558 for a primary endpoint of PFS2 in colorectal cancer.
#' 
#' @source
#' Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with
#' capecitabine and bevacizumab in metastatic colorectal cancer
#' (CAIRO3): a phase 3 randomised controlled trial of the Dutch
#' Colorectal Cancer Group. Lancet 2015; 385: 1843–52.
#' 
#' @format
#' A data frame of 557 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (maintenance, observation) \cr
#' }
#' 
#' @usage
#' CAIRO3_2A
#' 
#' @examples
#' summary(CAIRO3_2A)
#' 
#' kmplot(CAIRO3_2A)
"CAIRO3_2A"


#' CAIRO3, figure 2B
#' 
#' Kaplan-Meier digitized data from CAIRO3, figure 2B (PMID 25862517). A reported sample size of 558 for a primary endpoint of PFS2 in colorectal cancer.
#' 
#' @source
#' Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with
#' capecitabine and bevacizumab in metastatic colorectal cancer
#' (CAIRO3): a phase 3 randomised controlled trial of the Dutch
#' Colorectal Cancer Group. Lancet 2015; 385: 1843–52.
#' 
#' @format
#' A data frame of 557 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (maintenance, observation) \cr
#' }
#' 
#' @usage
#' CAIRO3_2B
#' 
#' @examples
#' summary(CAIRO3_2B)
#' 
#' kmplot(CAIRO3_2B)
"CAIRO3_2B"


#' CAIRO3, figure 2D
#' 
#' Kaplan-Meier digitized data from CAIRO3, figure 2D (PMID 25862517). A reported sample size of 558 for a primary endpoint of PFS2 in colorectal cancer.
#' 
#' @source
#' Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with
#' capecitabine and bevacizumab in metastatic colorectal cancer
#' (CAIRO3): a phase 3 randomised controlled trial of the Dutch
#' Colorectal Cancer Group. Lancet 2015; 385: 1843–52.
#' 
#' @format
#' A data frame of 557 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (maintenance, observation) \cr
#' }
#' 
#' @usage
#' CAIRO3_2D
#' 
#' @examples
#' summary(CAIRO3_2D)
#' 
#' kmplot(CAIRO3_2D)
"CAIRO3_2D"


#' CALGB40502, figure 2A
#' 
#' Kaplan-Meier digitized data from CALGB40502, figure 2A (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III
#' Trial of Paclitaxel Once Per Week Compared With Nanoparticle
#' Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With
#' Bevacizumab As First-Line Chemotherapy for Locally Recurrent or
#' Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
#' Oncol 2015; 33: 2361–9.
#' 
#' @format
#' A data frame of 487 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ixabepilone, p1) \cr
#' }
#' 
#' @usage
#' CALGB40502_2A
#' 
#' @examples
#' summary(CALGB40502_2A)
#' 
#' kmplot(CALGB40502_2A)
"CALGB40502_2A"


#' CALGB40502, figure 2B
#' 
#' Kaplan-Meier digitized data from CALGB40502, figure 2B (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III
#' Trial of Paclitaxel Once Per Week Compared With Nanoparticle
#' Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With
#' Bevacizumab As First-Line Chemotherapy for Locally Recurrent or
#' Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
#' Oncol 2015; 33: 2361–9.
#' 
#' @format
#' A data frame of 542 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (nab_paclitaxel, p1) \cr
#' }
#' 
#' @usage
#' CALGB40502_2B
#' 
#' @examples
#' summary(CALGB40502_2B)
#' 
#' kmplot(CALGB40502_2B)
"CALGB40502_2B"


#' CALGB40502, figure 2C
#' 
#' Kaplan-Meier digitized data from CALGB40502, figure 2C (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III
#' Trial of Paclitaxel Once Per Week Compared With Nanoparticle
#' Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With
#' Bevacizumab As First-Line Chemotherapy for Locally Recurrent or
#' Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
#' Oncol 2015; 33: 2361–9.
#' 
#' @format
#' A data frame of 487 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ixabepilone, p1) \cr
#' }
#' 
#' @usage
#' CALGB40502_2C
#' 
#' @examples
#' summary(CALGB40502_2C)
#' 
#' kmplot(CALGB40502_2C)
"CALGB40502_2C"


#' CALGB40502, figure 2D
#' 
#' Kaplan-Meier digitized data from CALGB40502, figure 2D (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III
#' Trial of Paclitaxel Once Per Week Compared With Nanoparticle
#' Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With
#' Bevacizumab As First-Line Chemotherapy for Locally Recurrent or
#' Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
#' Oncol 2015; 33: 2361–9.
#' 
#' @format
#' A data frame of 542 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (nab_paclitaxel, p1) \cr
#' }
#' 
#' @usage
#' CALGB40502_2D
#' 
#' @examples
#' summary(CALGB40502_2D)
#' 
#' kmplot(CALGB40502_2D)
"CALGB40502_2D"


#' CALGB40503, figure 2A
#' 
#' Kaplan-Meier digitized data from CALGB40503, figure 2A (PMID 27138575). A reported sample size of 350 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Dickler MN, Barry WT, Cirrincione CT, et al. Phase III Trial
#' Evaluating Letrozole As First-Line Endocrine Therapy With or Without
#' Bevacizumab for the Treatment of Postmenopausal Women With Hormone
#' Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503
#' (Alliance). J Clin Oncol 2016; 34: 2602–9.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, l_b) \cr
#' }
#' 
#' @usage
#' CALGB40503_2A
#' 
#' @examples
#' summary(CALGB40503_2A)
#' 
#' kmplot(CALGB40503_2A)
"CALGB40503_2A"


#' CALGB40503, figure 2B
#' 
#' Kaplan-Meier digitized data from CALGB40503, figure 2B (PMID 27138575). A reported sample size of 350 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Dickler MN, Barry WT, Cirrincione CT, et al. Phase III Trial
#' Evaluating Letrozole As First-Line Endocrine Therapy With or Without
#' Bevacizumab for the Treatment of Postmenopausal Women With Hormone
#' Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503
#' (Alliance). J Clin Oncol 2016; 34: 2602–9.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, l_b) \cr
#' }
#' 
#' @usage
#' CALGB40503_2B
#' 
#' @examples
#' summary(CALGB40503_2B)
#' 
#' kmplot(CALGB40503_2B)
"CALGB40503_2B"


#' CALGB90202, figure 2B
#' 
#' Kaplan-Meier digitized data from CALGB90202, figure 2B (PMID 24590644). A reported sample size of 645 for a primary endpoint of time_SRE in prostate cancer.
#' 
#' @source
#' Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of
#' early zoledronic acid in men with castration-sensitive prostate
#' cancer and bone metastases: results of CALGB 90202 (alliance). J Clin
#' Oncol 2014; 32: 1143–50.
#' 
#' @format
#' A data frame of 645 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, za) \cr
#' }
#' 
#' @usage
#' CALGB90202_2B
#' 
#' @examples
#' summary(CALGB90202_2B)
#' 
#' kmplot(CALGB90202_2B)
"CALGB90202_2B"


#' CALGB90202, figure 2C
#' 
#' Kaplan-Meier digitized data from CALGB90202, figure 2C (PMID 24590644). A reported sample size of 645 for a primary endpoint of time_SRE in prostate cancer.
#' 
#' @source
#' Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of
#' early zoledronic acid in men with castration-sensitive prostate
#' cancer and bone metastases: results of CALGB 90202 (alliance). J Clin
#' Oncol 2014; 32: 1143–50.
#' 
#' @format
#' A data frame of 645 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, za) \cr
#' }
#' 
#' @usage
#' CALGB90202_2C
#' 
#' @examples
#' summary(CALGB90202_2C)
#' 
#' kmplot(CALGB90202_2C)
"CALGB90202_2C"


#' CBCSG006, figure 2A
#' 
#' Kaplan-Meier digitized data from CBCSG006, figure 2A (PMID 25795409). A reported sample size of 240 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Hu X-C, Zhang J, Xu B-H, et al. Cisplatin plus gemcitabine versus
#' paclitaxel plus gemcitabine as first-line therapy for metastatic
#' triple-negative breast cancer (CBCSG006): a randomised, open-label,
#' multicentre, phase 3 trial. Lancet Oncol 2015; 16: 436–46.
#' 
#' @format
#' A data frame of 236 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cis_gemcitabine, paclitaxel_gemcitabine) \cr
#' }
#' 
#' @usage
#' CBCSG006_2A
#' 
#' @examples
#' summary(CBCSG006_2A)
#' 
#' kmplot(CBCSG006_2A)
"CBCSG006_2A"


#' CBCSG006, figure 2B
#' 
#' Kaplan-Meier digitized data from CBCSG006, figure 2B (PMID 25795409). A reported sample size of 240 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Hu X-C, Zhang J, Xu B-H, et al. Cisplatin plus gemcitabine versus
#' paclitaxel plus gemcitabine as first-line therapy for metastatic
#' triple-negative breast cancer (CBCSG006): a randomised, open-label,
#' multicentre, phase 3 trial. Lancet Oncol 2015; 16: 436–46.
#' 
#' @format
#' A data frame of 236 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cis_gemcitabine, paclitaxel_gemcitabine) \cr
#' }
#' 
#' @usage
#' CBCSG006_2B
#' 
#' @examples
#' summary(CBCSG006_2B)
#' 
#' kmplot(CBCSG006_2B)
"CBCSG006_2B"


#' CEREBEL, figure 2A
#' 
#' Kaplan-Meier digitized data from CEREBEL, figure 2A (PMID 25605838). A reported sample size of 540 for a primary endpoint of Incidence_CNSmets in breast cancer.
#' 
#' @source
#' Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): A Phase
#' III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine
#' Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal
#' Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin
#' Oncol 2015; 33: 1564–73.
#' 
#' @format
#' A data frame of 540 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lapatinib_cape, trastuzumab_cape) \cr
#' }
#' 
#' @usage
#' CEREBEL_2A
#' 
#' @examples
#' summary(CEREBEL_2A)
#' 
#' kmplot(CEREBEL_2A)
"CEREBEL_2A"


#' CEREBEL, figure 2B
#' 
#' Kaplan-Meier digitized data from CEREBEL, figure 2B (PMID 25605838). A reported sample size of 540 for a primary endpoint of Incidence_CNSmets in breast cancer.
#' 
#' @source
#' Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): A Phase
#' III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine
#' Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal
#' Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin
#' Oncol 2015; 33: 1564–73.
#' 
#' @format
#' A data frame of 540 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lapatinib_cape, trastuzumab_cape) \cr
#' }
#' 
#' @usage
#' CEREBEL_2B
#' 
#' @examples
#' summary(CEREBEL_2B)
#' 
#' kmplot(CEREBEL_2B)
"CEREBEL_2B"


#' Checkmate017, figure 1
#' 
#' Kaplan-Meier digitized data from Checkmate017, figure 1 (PMID 26028407). A reported sample size of 272 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in
#' Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;
#' 373: 123–35.
#' 
#' @format
#' A data frame of 272 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr
#' }
#' 
#' @usage
#' Checkmate017_1
#' 
#' @examples
#' summary(Checkmate017_1)
#' 
#' kmplot(Checkmate017_1)
"Checkmate017_1"


#' Checkmate017, figure 2B
#' 
#' Kaplan-Meier digitized data from Checkmate017, figure 2B (PMID 26028407). A reported sample size of 272 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in
#' Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;
#' 373: 123–35.
#' 
#' @format
#' A data frame of 272 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr
#' }
#' 
#' @usage
#' Checkmate017_2B
#' 
#' @examples
#' summary(Checkmate017_2B)
#' 
#' kmplot(Checkmate017_2B)
"Checkmate017_2B"


#' Checkmate057, figure 1A
#' 
#' Kaplan-Meier digitized data from Checkmate057, figure 1A (PMID 26412456). A reported sample size of 582 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in
#' Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;
#' 373: 1627–39.
#' 
#' @format
#' A data frame of 582 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr
#' }
#' 
#' @usage
#' Checkmate057_1A
#' 
#' @examples
#' summary(Checkmate057_1A)
#' 
#' kmplot(Checkmate057_1A)
"Checkmate057_1A"


#' Checkmate057, figure 1C
#' 
#' Kaplan-Meier digitized data from Checkmate057, figure 1C (PMID 26412456). A reported sample size of 582 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in
#' Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;
#' 373: 1627–39.
#' 
#' @format
#' A data frame of 582 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr
#' }
#' 
#' @usage
#' Checkmate057_1C
#' 
#' @examples
#' summary(Checkmate057_1C)
#' 
#' kmplot(Checkmate057_1C)
"Checkmate057_1C"


#' CHHiP(a), figure 2A
#' 
#' Kaplan-Meier digitized data from CHHiP(a), figure 2A (PMID 27339115). A reported sample size of 3,216 for a primary endpoint of bRFS in prostate cancer.
#' 
#' @source
#' Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
#' hypofractionated high-dose intensity-modulated radiotherapy for
#' prostate cancer: 5-year outcomes of the randomised, non-inferiority,
#' phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–60.
#' 
#' @format
#' A data frame of 2,139 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab RFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (60gy, 74gy) \cr
#' }
#' 
#' @usage
#' `CHHiP(a)_2A`
#' 
#' @examples
#' summary(`CHHiP(a)_2A`)
#' 
#' kmplot(`CHHiP(a)_2A`)
"CHHiP(a)_2A"


#' CHHiP(a), figure 2B
#' 
#' Kaplan-Meier digitized data from CHHiP(a), figure 2B (PMID 27339115). A reported sample size of 3,216 for a primary endpoint of bRFS in prostate cancer.
#' 
#' @source
#' Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
#' hypofractionated high-dose intensity-modulated radiotherapy for
#' prostate cancer: 5-year outcomes of the randomised, non-inferiority,
#' phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–60.
#' 
#' @format
#' A data frame of 2,139 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (60gy, 74gy) \cr
#' }
#' 
#' @usage
#' `CHHiP(a)_2B`
#' 
#' @examples
#' summary(`CHHiP(a)_2B`)
#' 
#' kmplot(`CHHiP(a)_2B`)
"CHHiP(a)_2B"


#' CHHiP(b), figure 2A
#' 
#' Kaplan-Meier digitized data from CHHiP(b), figure 2A (PMID 27339115). A reported sample size of 3,216 for a primary endpoint of bRFS in prostate cancer.
#' 
#' @source
#' Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
#' hypofractionated high-dose intensity-modulated radiotherapy for
#' prostate cancer: 5-year outcomes of the randomised, non-inferiority,
#' phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–60.
#' 
#' @format
#' A data frame of 2,142 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab RFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (57gy, 74gy) \cr
#' }
#' 
#' @usage
#' `CHHiP(b)_2A`
#' 
#' @examples
#' summary(`CHHiP(b)_2A`)
#' 
#' kmplot(`CHHiP(b)_2A`)
"CHHiP(b)_2A"


#' CHHiP(b), figure 2B
#' 
#' Kaplan-Meier digitized data from CHHiP(b), figure 2B (PMID 27339115). A reported sample size of 3,216 for a primary endpoint of bRFS in prostate cancer.
#' 
#' @source
#' Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
#' hypofractionated high-dose intensity-modulated radiotherapy for
#' prostate cancer: 5-year outcomes of the randomised, non-inferiority,
#' phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–60.
#' 
#' @format
#' A data frame of 2,142 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (57gy, 74gy) \cr
#' }
#' 
#' @usage
#' `CHHiP(b)_2B`
#' 
#' @examples
#' summary(`CHHiP(b)_2B`)
#' 
#' kmplot(`CHHiP(b)_2B`)
"CHHiP(b)_2B"


#' Chronicle, figure 2A
#' 
#' Kaplan-Meier digitized data from Chronicle, figure 2A (PMID 24718885). A reported sample size of 113 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a
#' randomised phase III trial in locally advanced rectal cancer after
#' neoadjuvant chemoradiation randomising postoperative adjuvant
#' capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014;
#' 25: 1356–62.
#' 
#' @format
#' A data frame of 113 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (capecitabine_oxaliplatin, follow_up_only) \cr
#' }
#' 
#' @usage
#' Chronicle_2A
#' 
#' @examples
#' summary(Chronicle_2A)
#' 
#' kmplot(Chronicle_2A)
"Chronicle_2A"


#' Chronicle, figure 2B
#' 
#' Kaplan-Meier digitized data from Chronicle, figure 2B (PMID 24718885). A reported sample size of 113 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a
#' randomised phase III trial in locally advanced rectal cancer after
#' neoadjuvant chemoradiation randomising postoperative adjuvant
#' capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014;
#' 25: 1356–62.
#' 
#' @format
#' A data frame of 113 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (capecitabine_oxaliplatin, follow_up_only) \cr
#' }
#' 
#' @usage
#' Chronicle_2B
#' 
#' @examples
#' summary(Chronicle_2B)
#' 
#' kmplot(Chronicle_2B)
"Chronicle_2B"


#' CLEOPATRA, figure 2A
#' 
#' Kaplan-Meier digitized data from CLEOPATRA, figure 2A (PMID 25693012). A reported sample size of 808 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and
#' docetaxel in HER2-positive metastatic breast cancer. N Engl J Med
#' 2015; 372: 724–34.
#' 
#' @format
#' A data frame of 808 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, pertuzumab) \cr
#' }
#' 
#' @usage
#' CLEOPATRA_2A
#' 
#' @examples
#' summary(CLEOPATRA_2A)
#' 
#' kmplot(CLEOPATRA_2A)
"CLEOPATRA_2A"


#' CLEOPATRA, figure 3A
#' 
#' Kaplan-Meier digitized data from CLEOPATRA, figure 3A (PMID 25693012). A reported sample size of 808 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and
#' docetaxel in HER2-positive metastatic breast cancer. N Engl J Med
#' 2015; 372: 724–34.
#' 
#' @format
#' A data frame of 808 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, pertuzumab) \cr
#' }
#' 
#' @usage
#' CLEOPATRA_3A
#' 
#' @examples
#' summary(CLEOPATRA_3A)
#' 
#' kmplot(CLEOPATRA_3A)
"CLEOPATRA_3A"


#' COMET1, figure 2A
#' 
#' Kaplan-Meier digitized data from COMET1, figure 2A (PMID 27400947). A reported sample size of 1,028 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Smith M, De Bono J, Sternberg C, et al. Phase III Study of
#' Cabozantinib in Previously Treated Metastatic Castration-Resistant
#' Prostate Cancer: COMET-1. J Clin Oncol 2016; 34: 3005–13.
#' 
#' @format
#' A data frame of 1,028 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cabozantinib, prednisone) \cr
#' }
#' 
#' @usage
#' COMET1_2A
#' 
#' @examples
#' summary(COMET1_2A)
#' 
#' kmplot(COMET1_2A)
"COMET1_2A"


#' COMET1, figure 2B
#' 
#' Kaplan-Meier digitized data from COMET1, figure 2B (PMID 27400947). A reported sample size of 1,028 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Smith M, De Bono J, Sternberg C, et al. Phase III Study of
#' Cabozantinib in Previously Treated Metastatic Castration-Resistant
#' Prostate Cancer: COMET-1. J Clin Oncol 2016; 34: 3005–13.
#' 
#' @format
#' A data frame of 1,028 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cabozantinib, prednisone) \cr
#' }
#' 
#' @usage
#' COMET1_2B
#' 
#' @examples
#' summary(COMET1_2B)
#' 
#' kmplot(COMET1_2B)
"COMET1_2B"


#' CONCEPT, figure 1A
#' 
#' Kaplan-Meier digitized data from CONCEPT, figure 1A (PMID 24608198). A reported sample size of 140 for a primary endpoint of TTF in colorectal cancer.
#' 
#' @source
#' Hochster HS, Grothey A, Hart L, et al. Improved time to treatment
#' failure with an intermittent oxaliplatin strategy: results of
#' CONcePT. Ann Oncol 2014; 25: 1172–8.
#' 
#' @format
#' A data frame of 139 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab TTF event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (co, io) \cr
#' }
#' 
#' @usage
#' CONCEPT_1A
#' 
#' @examples
#' summary(CONCEPT_1A)
#' 
#' kmplot(CONCEPT_1A)
"CONCEPT_1A"


#' CONCUR, figure 2A
#' 
#' Kaplan-Meier digitized data from CONCUR, figure 2A (PMID 25981818). A reported sample size of 243 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care
#' versus placebo plus best supportive care in Asian patients with
#' previously treated metastatic colorectal cancer (CONCUR): a
#' randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
#' Oncol 2015; 16: 619–29.
#' 
#' @format
#' A data frame of 204 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, regorafenib) \cr
#' }
#' 
#' @usage
#' CONCUR_2A
#' 
#' @examples
#' summary(CONCUR_2A)
#' 
#' kmplot(CONCUR_2A)
"CONCUR_2A"


#' CONCUR, figure 3A
#' 
#' Kaplan-Meier digitized data from CONCUR, figure 3A (PMID 25981818). A reported sample size of 243 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care
#' versus placebo plus best supportive care in Asian patients with
#' previously treated metastatic colorectal cancer (CONCUR): a
#' randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
#' Oncol 2015; 16: 619–29.
#' 
#' @format
#' A data frame of 204 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, regorafenib) \cr
#' }
#' 
#' @usage
#' CONCUR_3A
#' 
#' @examples
#' summary(CONCUR_3A)
#' 
#' kmplot(CONCUR_3A)
"CONCUR_3A"


#' COUAA202, figure 2
#' 
#' Kaplan-Meier digitized data from COUAA202, figure 2 (PMID 25601341). A reported sample size of 1,088 for a primary endpoint of rPFS/OS in prostate cancer.
#' 
#' @source
#' Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus
#' prednisone versus placebo plus prednisone in chemotherapy-naive men
#' with metastatic castration-resistant prostate cancer (COU-AA-302):
#' final overall survival analysis of a randomised, double-blind,
#' placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152–60.
#' 
#' @format
#' A data frame of 1,088 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (abiraterone, placebo) \cr
#' }
#' 
#' @usage
#' COUAA202_2
#' 
#' @examples
#' summary(COUAA202_2)
#' 
#' kmplot(COUAA202_2)
"COUAA202_2"


#' DART0105, figure 2A
#' 
#' Kaplan-Meier digitized data from DART0105, figure 2A (PMID 25702876). A reported sample size of 178 for a primary endpoint of bDFS in prostate cancer.
#' 
#' @source
#' Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy
#' with short-term or long-term androgen deprivation in localised
#' prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3
#' trial. Lancet Oncol 2015; 16: 320–7.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ltad, stad) \cr
#' }
#' 
#' @usage
#' DART0105_2A
#' 
#' @examples
#' summary(DART0105_2A)
#' 
#' kmplot(DART0105_2A)
"DART0105_2A"


#' DART0105, figure 2B
#' 
#' Kaplan-Meier digitized data from DART0105, figure 2B (PMID 25702876). A reported sample size of 178 for a primary endpoint of bDFS in prostate cancer.
#' 
#' @source
#' Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy
#' with short-term or long-term androgen deprivation in localised
#' prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3
#' trial. Lancet Oncol 2015; 16: 320–7.
#' 
#' @format
#' A data frame of 347 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ltad, stad) \cr
#' }
#' 
#' @usage
#' DART0105_2B
#' 
#' @examples
#' summary(DART0105_2B)
#' 
#' kmplot(DART0105_2B)
"DART0105_2B"


#' DELTA, figure 2A
#' 
#' Kaplan-Meier digitized data from DELTA, figure 2A (PMID 24841974). A reported sample size of 301 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of
#' erlotinib versus docetaxel as second- or third-line therapy in
#' patients with advanced non-small-cell lung cancer: Docetaxel and
#' Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902–8.
#' 
#' @format
#' A data frame of 301 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, erlotinib) \cr
#' }
#' 
#' @usage
#' DELTA_2A
#' 
#' @examples
#' summary(DELTA_2A)
#' 
#' kmplot(DELTA_2A)
"DELTA_2A"


#' DELTA, figure 2B
#' 
#' Kaplan-Meier digitized data from DELTA, figure 2B (PMID 24841974). A reported sample size of 301 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of
#' erlotinib versus docetaxel as second- or third-line therapy in
#' patients with advanced non-small-cell lung cancer: Docetaxel and
#' Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902–8.
#' 
#' @format
#' A data frame of 301 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, erlotinib) \cr
#' }
#' 
#' @usage
#' DELTA_2B
#' 
#' @examples
#' summary(DELTA_2B)
#' 
#' kmplot(DELTA_2B)
"DELTA_2B"


#' E1199(a), figure 2A
#' 
#' Kaplan-Meier digitized data from E1199(a), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,481 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (p1, p3) \cr
#' }
#' 
#' @usage
#' `E1199(a)_2A`
#' 
#' @examples
#' summary(`E1199(a)_2A`)
#' 
#' kmplot(`E1199(a)_2A`)
"E1199(a)_2A"


#' E1199(a), figure 2C
#' 
#' Kaplan-Meier digitized data from E1199(a), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,481 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (p1, p3) \cr
#' }
#' 
#' @usage
#' `E1199(a)_2C`
#' 
#' @examples
#' summary(`E1199(a)_2C`)
#' 
#' kmplot(`E1199(a)_2C`)
"E1199(a)_2C"


#' E1199(b), figure 2A
#' 
#' Kaplan-Meier digitized data from E1199(b), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,484 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d3, p3) \cr
#' }
#' 
#' @usage
#' `E1199(b)_2A`
#' 
#' @examples
#' summary(`E1199(b)_2A`)
#' 
#' kmplot(`E1199(b)_2A`)
"E1199(b)_2A"


#' E1199(b), figure 2C
#' 
#' Kaplan-Meier digitized data from E1199(b), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,484 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d3, p3) \cr
#' }
#' 
#' @usage
#' `E1199(b)_2C`
#' 
#' @examples
#' summary(`E1199(b)_2C`)
#' 
#' kmplot(`E1199(b)_2C`)
"E1199(b)_2C"


#' E1199(c), figure 2A
#' 
#' Kaplan-Meier digitized data from E1199(c), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,483 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, p3) \cr
#' }
#' 
#' @usage
#' `E1199(c)_2A`
#' 
#' @examples
#' summary(`E1199(c)_2A`)
#' 
#' kmplot(`E1199(c)_2A`)
"E1199(c)_2A"


#' E1199(c), figure 2C
#' 
#' Kaplan-Meier digitized data from E1199(c), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the
#' E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in
#' Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60.
#' 
#' @format
#' A data frame of 2,483 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (d1, p3) \cr
#' }
#' 
#' @usage
#' `E1199(c)_2C`
#' 
#' @examples
#' summary(`E1199(c)_2C`)
#' 
#' kmplot(`E1199(c)_2C`)
"E1199(c)_2C"


#' EAGLE, figure 1
#' 
#' Kaplan-Meier digitized data from EAGLE, figure 1 (PMID 25908603). A reported sample size of 369 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Iwamoto S, Takahashi T, Tamagawa H, et al. FOLFIRI plus bevacizumab
#' as second-line therapy in patients with metastatic colorectal cancer
#' after first-line bevacizumab plus oxaliplatin-based therapy: the
#' randomized phase III EAGLE study. Ann Oncol 2015; 26: 1427–33.
#' 
#' @format
#' A data frame of 368 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev10, bev5) \cr
#' }
#' 
#' @usage
#' EAGLE_1
#' 
#' @examples
#' summary(EAGLE_1)
#' 
#' kmplot(EAGLE_1)
"EAGLE_1"


#' ELDA, figure 1A
#' 
#' Kaplan-Meier digitized data from ELDA, figure 1A (PMID 25488686). A reported sample size of 302 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus CMF as
#' adjuvant chemotherapy for older women with early breast cancer: final
#' results of the randomized phase III ELDA trial. Ann Oncol 2015; 26:
#' 675–82.
#' 
#' @format
#' A data frame of 299 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cmf, wdocetaxel) \cr
#' }
#' 
#' @usage
#' ELDA_1A
#' 
#' @examples
#' summary(ELDA_1A)
#' 
#' kmplot(ELDA_1A)
"ELDA_1A"


#' ELDA, figure 1B
#' 
#' Kaplan-Meier digitized data from ELDA, figure 1B (PMID 25488686). A reported sample size of 302 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus CMF as
#' adjuvant chemotherapy for older women with early breast cancer: final
#' results of the randomized phase III ELDA trial. Ann Oncol 2015; 26:
#' 675–82.
#' 
#' @format
#' A data frame of 299 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cmf, wdocetaxel) \cr
#' }
#' 
#' @usage
#' ELDA_1B
#' 
#' @examples
#' summary(ELDA_1B)
#' 
#' kmplot(ELDA_1B)
"ELDA_1B"


#' ELM-PC4, figure 2A
#' 
#' Kaplan-Meier digitized data from ELM-PC4, figure 2A (PMID 25701170). A reported sample size of 1,560 for a primary endpoint of rPFS/OS in prostate cancer.
#' 
#' @source
#' Saad F, Fizazi K, Jinga V, et al. Orteronel plus prednisone in
#' patients with chemotherapy-naive metastatic castration-resistant
#' prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3,
#' randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 338–48.
#' 
#' @format
#' A data frame of 1,560 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (orteronel, placebo) \cr
#' }
#' 
#' @usage
#' `ELM-PC4_2A`
#' 
#' @examples
#' summary(`ELM-PC4_2A`)
#' 
#' kmplot(`ELM-PC4_2A`)
"ELM-PC4_2A"


#' ELM-PC4, figure 3A
#' 
#' Kaplan-Meier digitized data from ELM-PC4, figure 3A (PMID 25701170). A reported sample size of 1,560 for a primary endpoint of rPFS/OS in prostate cancer.
#' 
#' @source
#' Saad F, Fizazi K, Jinga V, et al. Orteronel plus prednisone in
#' patients with chemotherapy-naive metastatic castration-resistant
#' prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3,
#' randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 338–48.
#' 
#' @format
#' A data frame of 1,560 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (orteronel, placebo) \cr
#' }
#' 
#' @usage
#' `ELM-PC4_3A`
#' 
#' @examples
#' summary(`ELM-PC4_3A`)
#' 
#' kmplot(`ELM-PC4_3A`)
"ELM-PC4_3A"


#' ELM-PC5, figure 2A
#' 
#' Kaplan-Meier digitized data from ELM-PC5, figure 2A (PMID 25624429). A reported sample size of 1,099 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Fizazi K, Jones R, Oudard S, et al. Phase III, randomized,
#' double-blind, multicenter trial comparing orteronel (TAK-700) plus
#' prednisone with placebo plus prednisone in patients with metastatic
#' castration-resistant prostate cancer that has progressed during or
#' after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 33:
#' 723–31.
#' 
#' @format
#' A data frame of 1,099 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (orteronel, placebo) \cr
#' }
#' 
#' @usage
#' `ELM-PC5_2A`
#' 
#' @examples
#' summary(`ELM-PC5_2A`)
#' 
#' kmplot(`ELM-PC5_2A`)
"ELM-PC5_2A"


#' ELM-PC5, figure 2B
#' 
#' Kaplan-Meier digitized data from ELM-PC5, figure 2B (PMID 25624429). A reported sample size of 1,099 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Fizazi K, Jones R, Oudard S, et al. Phase III, randomized,
#' double-blind, multicenter trial comparing orteronel (TAK-700) plus
#' prednisone with placebo plus prednisone in patients with metastatic
#' castration-resistant prostate cancer that has progressed during or
#' after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 33:
#' 723–31.
#' 
#' @format
#' A data frame of 1,099 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (orteronel, placebo) \cr
#' }
#' 
#' @usage
#' `ELM-PC5_2B`
#' 
#' @examples
#' summary(`ELM-PC5_2B`)
#' 
#' kmplot(`ELM-PC5_2B`)
"ELM-PC5_2B"


#' ENESTg1, figure 2A
#' 
#' Kaplan-Meier digitized data from ENESTg1, figure 2A (PMID 25882987). A reported sample size of 647 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Blay J-Y, Shen L, Kang Y-K, et al. Nilotinib versus imatinib as
#' first-line therapy for patients with unresectable or metastatic
#' gastrointestinal stromal tumours (ENESTg1): a randomised phase 3
#' trial. Lancet Oncol 2015; 16: 550–60.
#' 
#' @format
#' A data frame of 644 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (imatinib, nilotinib) \cr
#' }
#' 
#' @usage
#' ENESTg1_2A
#' 
#' @examples
#' summary(ENESTg1_2A)
#' 
#' kmplot(ENESTg1_2A)
"ENESTg1_2A"


#' ENESTg1, figure 2B
#' 
#' Kaplan-Meier digitized data from ENESTg1, figure 2B (PMID 25882987). A reported sample size of 647 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Blay J-Y, Shen L, Kang Y-K, et al. Nilotinib versus imatinib as
#' first-line therapy for patients with unresectable or metastatic
#' gastrointestinal stromal tumours (ENESTg1): a randomised phase 3
#' trial. Lancet Oncol 2015; 16: 550–60.
#' 
#' @format
#' A data frame of 644 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (imatinib, nilotinib) \cr
#' }
#' 
#' @usage
#' ENESTg1_2B
#' 
#' @examples
#' summary(ENESTg1_2B)
#' 
#' kmplot(ENESTg1_2B)
"ENESTg1_2B"


#' ENSURE, figure 2A
#' 
#' Kaplan-Meier digitized data from ENSURE, figure 2A (PMID 26105600). A reported sample size of 217 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus
#' gemcitabine/cisplatin in patients with advanced EGFR
#' mutation-positive non-small-cell lung cancer: analyses from the phase
#' III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26:
#' 1883–9.
#' 
#' @format
#' A data frame of 217 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, gp) \cr
#' }
#' 
#' @usage
#' ENSURE_2A
#' 
#' @examples
#' summary(ENSURE_2A)
#' 
#' kmplot(ENSURE_2A)
"ENSURE_2A"


#' ENSURE, figure 3A
#' 
#' Kaplan-Meier digitized data from ENSURE, figure 3A (PMID 26105600). A reported sample size of 217 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus
#' gemcitabine/cisplatin in patients with advanced EGFR
#' mutation-positive non-small-cell lung cancer: analyses from the phase
#' III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26:
#' 1883–9.
#' 
#' @format
#' A data frame of 217 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, gp) \cr
#' }
#' 
#' @usage
#' ENSURE_3A
#' 
#' @examples
#' summary(ENSURE_3A)
#' 
#' kmplot(ENSURE_3A)
"ENSURE_3A"


#' EORTC22881, figure 2
#' 
#' Kaplan-Meier digitized data from EORTC22881, figure 2 (PMID 25500422). A reported sample size of 2,657 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation
#' with or without a boost for patients treated with breast-conserving
#' surgery for early breast cancer: 20-year follow-up of a randomised
#' phase 3 trial. Lancet Oncol 2015; 16: 47–56.
#' 
#' @format
#' A data frame of 5,318 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (boost, no boost) \cr
#' }
#' 
#' @usage
#' EORTC22881_2
#' 
#' @examples
#' summary(EORTC22881_2)
#' 
#' kmplot(EORTC22881_2)
"EORTC22881_2"


#' ERCC1, figure 2A
#' 
#' Kaplan-Meier digitized data from ERCC1, figure 2A (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective
#' Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum
#' Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J
#' Clin Oncol 2017; 35: 402–11.
#' 
#' @format
#' A data frame of 464 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin, p1) \cr
#' }
#' 
#' @usage
#' ERCC1_2A
#' 
#' @examples
#' summary(ERCC1_2A)
#' 
#' kmplot(ERCC1_2A)
"ERCC1_2A"


#' ERCC1, figure 2B
#' 
#' Kaplan-Meier digitized data from ERCC1, figure 2B (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective
#' Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum
#' Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J
#' Clin Oncol 2017; 35: 402–11.
#' 
#' @format
#' A data frame of 468 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin_pemetrexed, p1) \cr
#' }
#' 
#' @usage
#' ERCC1_2B
#' 
#' @examples
#' summary(ERCC1_2B)
#' 
#' kmplot(ERCC1_2B)
"ERCC1_2B"


#' ERCC1, figure 2C
#' 
#' Kaplan-Meier digitized data from ERCC1, figure 2C (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective
#' Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum
#' Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J
#' Clin Oncol 2017; 35: 402–11.
#' 
#' @format
#' A data frame of 168 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin, paclitaxel_gemcitabine) \cr
#' }
#' 
#' @usage
#' ERCC1_2C
#' 
#' @examples
#' summary(ERCC1_2C)
#' 
#' kmplot(ERCC1_2C)
"ERCC1_2C"


#' ERCC1, figure 2D
#' 
#' Kaplan-Meier digitized data from ERCC1, figure 2D (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective
#' Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum
#' Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J
#' Clin Oncol 2017; 35: 402–11.
#' 
#' @format
#' A data frame of 173 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin, p1) \cr
#' }
#' 
#' @usage
#' ERCC1_2D
#' 
#' @examples
#' summary(ERCC1_2D)
#' 
#' kmplot(ERCC1_2D)
"ERCC1_2D"


#' ESPATUE, figure 2
#' 
#' Kaplan-Meier digitized data from ESPATUE, figure 2 (PMID 26527789). A reported sample size of 246 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Eberhardt WEE, Pöttgen C, Gauler TC, et al. Phase III Study of
#' Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in
#' Patients With Resectable Stage IIIA(N2) and Selected IIIB
#' Non-Small-Cell Lung Cancer After Induction Chemotherapy and
#' Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33:
#' 4194–201.
#' 
#' @format
#' A data frame of 161 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armb) \cr
#' }
#' 
#' @usage
#' ESPATUE_2
#' 
#' @examples
#' summary(ESPATUE_2)
#' 
#' kmplot(ESPATUE_2)
"ESPATUE_2"


#' ESPATUE, figure 3
#' 
#' Kaplan-Meier digitized data from ESPATUE, figure 3 (PMID 26527789). A reported sample size of 246 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Eberhardt WEE, Pöttgen C, Gauler TC, et al. Phase III Study of
#' Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in
#' Patients With Resectable Stage IIIA(N2) and Selected IIIB
#' Non-Small-Cell Lung Cancer After Induction Chemotherapy and
#' Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33:
#' 4194–201.
#' 
#' @format
#' A data frame of 161 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armb) \cr
#' }
#' 
#' @usage
#' ESPATUE_3
#' 
#' @examples
#' summary(ESPATUE_3)
#' 
#' kmplot(ESPATUE_3)
"ESPATUE_3"


#' ExteNET, figure 2A
#' 
#' Kaplan-Meier digitized data from ExteNET, figure 2A (PMID 26874901). A reported sample size of 2,840 for a primary endpoint of iDFS in breast cancer.
#' 
#' @source
#' Chan A, Delaloge S, Holmes FA, et al. Neratinib after
#' trastuzumab-based adjuvant therapy in patients with HER2-positive
#' breast cancer (ExteNET): a multicentre, randomised, double-blind,
#' placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 367–77.
#' 
#' @format
#' A data frame of 2,840 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (neratinib, placebo) \cr
#' }
#' 
#' @usage
#' ExteNET_2A
#' 
#' @examples
#' summary(ExteNET_2A)
#' 
#' kmplot(ExteNET_2A)
"ExteNET_2A"


#' FALCON, figure 2
#' 
#' Kaplan-Meier digitized data from FALCON, figure 2 (PMID 27908454). A reported sample size of 462 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg
#' versus anastrozole 1 mg for hormone receptor-positive advanced breast
#' cancer (FALCON): an international, randomised, double-blind, phase 3
#' trial. Lancet 2016; 388: 2997–3005.
#' 
#' @format
#' A data frame of 462 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (anastrazole, fulvestrant) \cr
#' }
#' 
#' @usage
#' FALCON_2
#' 
#' @examples
#' summary(FALCON_2)
#' 
#' kmplot(FALCON_2)
"FALCON_2"


#' FFCD2001, figure S1A
#' 
#' Kaplan-Meier digitized data from FFCD2001, figure S1A (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III
#' trial in elderly patients comparing LV5FU2 with or without irinotecan
#' for first-line treatment of metastatic colorectal cancer (FFCD
#' 2001-02). Ann Oncol 2016; 27: 121–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (fu, iri) \cr
#' }
#' 
#' @usage
#' FFCD2001_S1A
#' 
#' @examples
#' summary(FFCD2001_S1A)
#' 
#' kmplot(FFCD2001_S1A)
"FFCD2001_S1A"


#' FFCD2001, figure S1B
#' 
#' Kaplan-Meier digitized data from FFCD2001, figure S1B (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III
#' trial in elderly patients comparing LV5FU2 with or without irinotecan
#' for first-line treatment of metastatic colorectal cancer (FFCD
#' 2001-02). Ann Oncol 2016; 27: 121–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (fu, iri) \cr
#' }
#' 
#' @usage
#' FFCD2001_S1B
#' 
#' @examples
#' summary(FFCD2001_S1B)
#' 
#' kmplot(FFCD2001_S1B)
"FFCD2001_S1B"


#' FFCD2001, figure S1C
#' 
#' Kaplan-Meier digitized data from FFCD2001, figure S1C (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III
#' trial in elderly patients comparing LV5FU2 with or without irinotecan
#' for first-line treatment of metastatic colorectal cancer (FFCD
#' 2001-02). Ann Oncol 2016; 27: 121–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (classic, simplified) \cr
#' }
#' 
#' @usage
#' FFCD2001_S1C
#' 
#' @examples
#' summary(FFCD2001_S1C)
#' 
#' kmplot(FFCD2001_S1C)
"FFCD2001_S1C"


#' FFCD2001, figure S1D
#' 
#' Kaplan-Meier digitized data from FFCD2001, figure S1D (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III
#' trial in elderly patients comparing LV5FU2 with or without irinotecan
#' for first-line treatment of metastatic colorectal cancer (FFCD
#' 2001-02). Ann Oncol 2016; 27: 121–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (classic, simplified) \cr
#' }
#' 
#' @usage
#' FFCD2001_S1D
#' 
#' @examples
#' summary(FFCD2001_S1D)
#' 
#' kmplot(FFCD2001_S1D)
"FFCD2001_S1D"


#' FIRE3, figure 2A
#' 
#' Kaplan-Meier digitized data from FIRE3, figure 2A (PMID 25088940). A reported sample size of 592 for a primary endpoint of objective_response in colorectal cancer.
#' 
#' @source
#' Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus
#' cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for
#' patients with metastatic colorectal cancer (FIRE-3): a randomised,
#' open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065–75.
#' 
#' @format
#' A data frame of 592 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfiri_cetuximab) \cr
#' }
#' 
#' @usage
#' FIRE3_2A
#' 
#' @examples
#' summary(FIRE3_2A)
#' 
#' kmplot(FIRE3_2A)
"FIRE3_2A"


#' FIRE3, figure 2B
#' 
#' Kaplan-Meier digitized data from FIRE3, figure 2B (PMID 25088940). A reported sample size of 592 for a primary endpoint of objective_response in colorectal cancer.
#' 
#' @source
#' Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus
#' cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for
#' patients with metastatic colorectal cancer (FIRE-3): a randomised,
#' open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065–75.
#' 
#' @format
#' A data frame of 592 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfiri_cetuximab) \cr
#' }
#' 
#' @usage
#' FIRE3_2B
#' 
#' @examples
#' summary(FIRE3_2B)
#' 
#' kmplot(FIRE3_2B)
"FIRE3_2B"


#' GECESTRO-APBI, figure 3
#' 
#' Kaplan-Meier digitized data from GECESTRO-APBI, figure 3 (PMID 26494415). A reported sample size of 551 for a primary endpoint of LR in breast cancer.
#' 
#' @source
#' Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated
#' partial breast irradiation using sole interstitial multicatheter
#' brachytherapy versus whole-breast irradiation with boost after
#' breast-conserving surgery for low-risk invasive and in-situ carcinoma
#' of the female breast: a randomised, phase 3, non-inferiority trial.
#' Lancet 2016; 387: 229–38.
#' 
#' @format
#' A data frame of 1,184 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (apbi, wbi) \cr
#' }
#' 
#' @usage
#' `GECESTRO-APBI_3`
#' 
#' @examples
#' summary(`GECESTRO-APBI_3`)
#' 
#' kmplot(`GECESTRO-APBI_3`)
"GECESTRO-APBI_3"


#' GECESTRO-APBI, figure 4
#' 
#' Kaplan-Meier digitized data from GECESTRO-APBI, figure 4 (PMID 26494415). A reported sample size of 551 for a primary endpoint of LR in breast cancer.
#' 
#' @source
#' Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated
#' partial breast irradiation using sole interstitial multicatheter
#' brachytherapy versus whole-breast irradiation with boost after
#' breast-conserving surgery for low-risk invasive and in-situ carcinoma
#' of the female breast: a randomised, phase 3, non-inferiority trial.
#' Lancet 2016; 387: 229–38.
#' 
#' @format
#' A data frame of 1,184 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (apbi, wbi) \cr
#' }
#' 
#' @usage
#' `GECESTRO-APBI_4`
#' 
#' @examples
#' summary(`GECESTRO-APBI_4`)
#' 
#' kmplot(`GECESTRO-APBI_4`)
"GECESTRO-APBI_4"


#' GEICAM2003, figure 2A
#' 
#' Kaplan-Meier digitized data from GEICAM2003, figure 2A (PMID 26416999). A reported sample size of 1,384 for a primary endpoint of iDFS in breast cancer.
#' 
#' @source
#' Martín M, Ruiz Simón A, Ruiz Borrego M, et al. Epirubicin Plus
#' Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus
#' Docetaxel Followed by Capecitabine As Adjuvant Therapy for
#' Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10
#' Study. J Clin Oncol 2015; 33: 3788–95.
#' 
#' @format
#' A data frame of 1,384 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ec_t, et_x) \cr
#' }
#' 
#' @usage
#' GEICAM2003_2A
#' 
#' @examples
#' summary(GEICAM2003_2A)
#' 
#' kmplot(GEICAM2003_2A)
"GEICAM2003_2A"


#' GEICAM2003, figure 2B
#' 
#' Kaplan-Meier digitized data from GEICAM2003, figure 2B (PMID 26416999). A reported sample size of 1,384 for a primary endpoint of iDFS in breast cancer.
#' 
#' @source
#' Martín M, Ruiz Simón A, Ruiz Borrego M, et al. Epirubicin Plus
#' Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus
#' Docetaxel Followed by Capecitabine As Adjuvant Therapy for
#' Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10
#' Study. J Clin Oncol 2015; 33: 3788–95.
#' 
#' @format
#' A data frame of 1,384 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ec_t, et_x) \cr
#' }
#' 
#' @usage
#' GEICAM2003_2B
#' 
#' @examples
#' summary(GEICAM2003_2B)
#' 
#' kmplot(GEICAM2003_2B)
"GEICAM2003_2B"


#' GETUG12, figure 2
#' 
#' Kaplan-Meier digitized data from GETUG12, figure 2 (PMID 26028518). A reported sample size of 207 for a primary endpoint of RFS in prostate cancer.
#' 
#' @source
#' Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy
#' plus docetaxel and estramustine versus androgen deprivation therapy
#' alone for high-risk localised prostate cancer (GETUG 12): a phase 3
#' randomised controlled trial. Lancet Oncol 2015; 16: 787–94.
#' 
#' @format
#' A data frame of 413 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab RFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (adt, adt_de) \cr
#' }
#' 
#' @usage
#' GETUG12_2
#' 
#' @examples
#' summary(GETUG12_2)
#' 
#' kmplot(GETUG12_2)
"GETUG12_2"


#' GETUG16, figure 2
#' 
#' Kaplan-Meier digitized data from GETUG16, figure 2 (PMID 27160475). A reported sample size of 743 for a primary endpoint of PFS in prostate cancer.
#' 
#' @source
#' Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with
#' or without short-term hormone therapy for rising prostate-specific
#' antigen concentration after radical prostatectomy (GETUG-AFU 16): a
#' randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016;
#' 17: 747–56.
#' 
#' @format
#' A data frame of 730 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (rt, rt_goserelin) \cr
#' }
#' 
#' @usage
#' GETUG16_2
#' 
#' @examples
#' summary(GETUG16_2)
#' 
#' kmplot(GETUG16_2)
"GETUG16_2"


#' GIM, figure 3
#' 
#' Kaplan-Meier digitized data from GIM, figure 3 (PMID 26720025). A reported sample size of 281 for a primary endpoint of Incidence_chemo-induced menopause in breast cancer.
#' 
#' @source
#' Lambertini M, Boni L, Michelotti A, et al. Ovarian Suppression With
#' Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term
#' Ovarian Function, Pregnancies, and Disease-Free Survival: A
#' Randomized Clinical Trial. JAMA 2015; 314: 2632–40.
#' 
#' @format
#' A data frame of 281 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, lhrha) \cr
#' }
#' 
#' @usage
#' GIM_3
#' 
#' @examples
#' summary(GIM_3)
#' 
#' kmplot(GIM_3)
"GIM_3"


#' GIM2, figure 2A
#' 
#' Kaplan-Meier digitized data from GIM2, figure 2A (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and
#' dose-dense chemotherapy in adjuvant treatment of patients with
#' early-stage breast cancer: an open-label, 2 × 2 factorial, randomised
#' phase 3 trial. Lancet 2015; 385: 1863–72.
#' 
#' @format
#' A data frame of 2,091 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ec_p, fec_p) \cr
#' }
#' 
#' @usage
#' GIM2_2A
#' 
#' @examples
#' summary(GIM2_2A)
#' 
#' kmplot(GIM2_2A)
"GIM2_2A"


#' GIM2, figure 2B
#' 
#' Kaplan-Meier digitized data from GIM2, figure 2B (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and
#' dose-dense chemotherapy in adjuvant treatment of patients with
#' early-stage breast cancer: an open-label, 2 × 2 factorial, randomised
#' phase 3 trial. Lancet 2015; 385: 1863–72.
#' 
#' @format
#' A data frame of 2,091 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ec_p, fec_p) \cr
#' }
#' 
#' @usage
#' GIM2_2B
#' 
#' @examples
#' summary(GIM2_2B)
#' 
#' kmplot(GIM2_2B)
"GIM2_2B"


#' GIM2, figure 2C
#' 
#' Kaplan-Meier digitized data from GIM2, figure 2C (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and
#' dose-dense chemotherapy in adjuvant treatment of patients with
#' early-stage breast cancer: an open-label, 2 × 2 factorial, randomised
#' phase 3 trial. Lancet 2015; 385: 1863–72.
#' 
#' @format
#' A data frame of 2,003 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (q2, q3) \cr
#' }
#' 
#' @usage
#' GIM2_2C
#' 
#' @examples
#' summary(GIM2_2C)
#' 
#' kmplot(GIM2_2C)
"GIM2_2C"


#' GIM2, figure 2D
#' 
#' Kaplan-Meier digitized data from GIM2, figure 2D (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and
#' dose-dense chemotherapy in adjuvant treatment of patients with
#' early-stage breast cancer: an open-label, 2 × 2 factorial, randomised
#' phase 3 trial. Lancet 2015; 385: 1863–72.
#' 
#' @format
#' A data frame of 2,003 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (q2, q3) \cr
#' }
#' 
#' @usage
#' GIM2_2D
#' 
#' @examples
#' summary(GIM2_2D)
#' 
#' kmplot(GIM2_2D)
"GIM2_2D"


#' HYPRO, figure 2A
#' 
#' Kaplan-Meier digitized data from HYPRO, figure 2A (PMID 27339116). A reported sample size of 804 for a primary endpoint of RFS in prostate cancer.
#' 
#' @source
#' Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus
#' conventionally fractionated radiotherapy for patients with localised
#' prostate cancer (HYPRO): final efficacy results from a randomised,
#' multicentre, open-label, phase 3 trial. Lancet Oncol 2016; 17:
#' 1061–9.
#' 
#' @format
#' A data frame of 804 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab RFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (conventional fractionated, hypofractionated) \cr
#' }
#' 
#' @usage
#' HYPRO_2A
#' 
#' @examples
#' summary(HYPRO_2A)
#' 
#' kmplot(HYPRO_2A)
"HYPRO_2A"


#' HYPRO, figure 2B
#' 
#' Kaplan-Meier digitized data from HYPRO, figure 2B (PMID 27339116). A reported sample size of 804 for a primary endpoint of RFS in prostate cancer.
#' 
#' @source
#' Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus
#' conventionally fractionated radiotherapy for patients with localised
#' prostate cancer (HYPRO): final efficacy results from a randomised,
#' multicentre, open-label, phase 3 trial. Lancet Oncol 2016; 17:
#' 1061–9.
#' 
#' @format
#' A data frame of 804 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (conventional fractionated, hypofractionated) \cr
#' }
#' 
#' @usage
#' HYPRO_2B
#' 
#' @examples
#' summary(HYPRO_2B)
#' 
#' kmplot(HYPRO_2B)
"HYPRO_2B"


#' IBCSG2200, figure 2A
#' 
#' Kaplan-Meier digitized data from IBCSG2200, figure 2A (PMID 27325862). A reported sample size of 1,086 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Colleoni M, Gray KP, Gelber S, et al. Low-Dose Oral Cyclophosphamide
#' and Methotrexate Maintenance for Hormone Receptor-Negative Early
#' Breast Cancer: International Breast Cancer Study Group Trial 22-00. J
#' Clin Oncol 2016; 34: 3400–8.
#' 
#' @format
#' A data frame of 1,081 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cm, no cm) \cr
#' }
#' 
#' @usage
#' IBCSG2200_2A
#' 
#' @examples
#' summary(IBCSG2200_2A)
#' 
#' kmplot(IBCSG2200_2A)
"IBCSG2200_2A"


#' IMELDA, figure 2A
#' 
#' Kaplan-Meier digitized data from IMELDA, figure 2A (PMID 25273343). A reported sample size of 284 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and
#' bevacizumab versus bevacizumab alone after initial first-line
#' bevacizumab and docetaxel for patients with HER2-negative metastatic
#' breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
#' Lancet Oncol 2014; 15: 1351–60.
#' 
#' @format
#' A data frame of 185 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bevacizumab, bevacizumab_capecitabine) \cr
#' }
#' 
#' @usage
#' IMELDA_2A
#' 
#' @examples
#' summary(IMELDA_2A)
#' 
#' kmplot(IMELDA_2A)
"IMELDA_2A"


#' IMELDA, figure 2B
#' 
#' Kaplan-Meier digitized data from IMELDA, figure 2B (PMID 25273343). A reported sample size of 284 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and
#' bevacizumab versus bevacizumab alone after initial first-line
#' bevacizumab and docetaxel for patients with HER2-negative metastatic
#' breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
#' Lancet Oncol 2014; 15: 1351–60.
#' 
#' @format
#' A data frame of 185 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bevacizumab, bevacizumab_capecitabine) \cr
#' }
#' 
#' @usage
#' IMELDA_2B
#' 
#' @examples
#' summary(IMELDA_2B)
#' 
#' kmplot(IMELDA_2B)
"IMELDA_2B"


#' IMPRESS, figure 2
#' 
#' Kaplan-Meier digitized data from IMPRESS, figure 2 (PMID 26159065). A reported sample size of 265 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Soria J-C, Wu Y-L, Nakagawa K, et al. Gefitinib plus chemotherapy
#' versus placebo plus chemotherapy in EGFR-mutation-positive
#' non-small-cell lung cancer after progression on first-line gefitinib
#' (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16: 990–8.
#' 
#' @format
#' A data frame of 265 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (gefitinib, placebo) \cr
#' }
#' 
#' @usage
#' IMPRESS_2
#' 
#' @examples
#' summary(IMPRESS_2)
#' 
#' kmplot(IMPRESS_2)
"IMPRESS_2"


#' INSPIRE, figure 2A
#' 
#' Kaplan-Meier digitized data from INSPIRE, figure 2A (PMID 25701171). A reported sample size of 633 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed
#' and cisplatin as first-line therapy in patients with stage IV
#' non-squamous non-small-cell lung cancer (INSPIRE): an open-label,
#' randomised, controlled phase 3 study. Lancet Oncol 2015; 16: 328–37.
#' 
#' @format
#' A data frame of 633 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ct, necitumumab_ct) \cr
#' }
#' 
#' @usage
#' INSPIRE_2A
#' 
#' @examples
#' summary(INSPIRE_2A)
#' 
#' kmplot(INSPIRE_2A)
"INSPIRE_2A"


#' INSPIRE, figure 2B
#' 
#' Kaplan-Meier digitized data from INSPIRE, figure 2B (PMID 25701171). A reported sample size of 633 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed
#' and cisplatin as first-line therapy in patients with stage IV
#' non-squamous non-small-cell lung cancer (INSPIRE): an open-label,
#' randomised, controlled phase 3 study. Lancet Oncol 2015; 16: 328–37.
#' 
#' @format
#' A data frame of 633 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ct, necitumumab_ct) \cr
#' }
#' 
#' @usage
#' INSPIRE_2B
#' 
#' @examples
#' summary(INSPIRE_2B)
#' 
#' kmplot(INSPIRE_2B)
"INSPIRE_2B"


#' INT0142, figure 2A
#' 
#' Kaplan-Meier digitized data from INT0142, figure 2A (PMID 25349302). A reported sample size of 345 for a primary endpoint of DFS/OS in breast cancer.
#' 
#' @source
#' Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of
#' tamoxifen versus tamoxifen plus ovarian function suppression in
#' premenopausal women with node-negative, hormone receptor-positive
#' breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative
#' Oncology Group. J Clin Oncol 2014; 32: 3948–58.
#' 
#' @format
#' A data frame of 337 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (tamoxifen, tamoxifen_ofs) \cr
#' }
#' 
#' @usage
#' INT0142_2A
#' 
#' @examples
#' summary(INT0142_2A)
#' 
#' kmplot(INT0142_2A)
"INT0142_2A"


#' INT0142, figure 2B
#' 
#' Kaplan-Meier digitized data from INT0142, figure 2B (PMID 25349302). A reported sample size of 345 for a primary endpoint of DFS/OS in breast cancer.
#' 
#' @source
#' Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of
#' tamoxifen versus tamoxifen plus ovarian function suppression in
#' premenopausal women with node-negative, hormone receptor-positive
#' breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative
#' Oncology Group. J Clin Oncol 2014; 32: 3948–58.
#' 
#' @format
#' A data frame of 337 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (tamoxifen, tamoxifen_ofs) \cr
#' }
#' 
#' @usage
#' INT0142_2B
#' 
#' @examples
#' summary(INT0142_2B)
#' 
#' kmplot(INT0142_2B)
"INT0142_2B"


#' ITACa, figure 2A
#' 
#' Kaplan-Meier digitized data from ITACa, figure 2A (PMID 25735317). A reported sample size of 376 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab
#' added to standard chemotherapy in metastatic colorectal cancer: final
#' results for first-line treatment from the ITACa randomized clinical
#' trial. Ann Oncol 2015; 26: 1201–7.
#' 
#' @format
#' A data frame of 370 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ct, ct_b) \cr
#' }
#' 
#' @usage
#' ITACa_2A
#' 
#' @examples
#' summary(ITACa_2A)
#' 
#' kmplot(ITACa_2A)
"ITACa_2A"


#' ITACa, figure 2B
#' 
#' Kaplan-Meier digitized data from ITACa, figure 2B (PMID 25735317). A reported sample size of 376 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab
#' added to standard chemotherapy in metastatic colorectal cancer: final
#' results for first-line treatment from the ITACa randomized clinical
#' trial. Ann Oncol 2015; 26: 1201–7.
#' 
#' @format
#' A data frame of 370 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ct, ct_b) \cr
#' }
#' 
#' @usage
#' ITACa_2B
#' 
#' @examples
#' summary(ITACa_2B)
#' 
#' kmplot(ITACa_2B)
"ITACa_2B"


#' JCOG0509, figure 2A
#' 
#' Kaplan-Meier digitized data from JCOG0509, figure 2A (PMID 24638015). A reported sample size of 284 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing
#' amrubicin plus cisplatin with irinotecan plus cisplatin in the
#' treatment of extensive-disease small-cell lung cancer: JCOG 0509. J
#' Clin Oncol 2014; 32: 1262–8.
#' 
#' @format
#' A data frame of 284 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (amrubicin_cisplatin, irinotecan_cisplatin) \cr
#' }
#' 
#' @usage
#' JCOG0509_2A
#' 
#' @examples
#' summary(JCOG0509_2A)
#' 
#' kmplot(JCOG0509_2A)
"JCOG0509_2A"


#' JCOG0509, figure 2B
#' 
#' Kaplan-Meier digitized data from JCOG0509, figure 2B (PMID 24638015). A reported sample size of 284 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing
#' amrubicin plus cisplatin with irinotecan plus cisplatin in the
#' treatment of extensive-disease small-cell lung cancer: JCOG 0509. J
#' Clin Oncol 2014; 32: 1262–8.
#' 
#' @format
#' A data frame of 284 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (amrubicin_cisplatin, irinotecan_cisplatin) \cr
#' }
#' 
#' @usage
#' JCOG0509_2B
#' 
#' @examples
#' summary(JCOG0509_2B)
#' 
#' kmplot(JCOG0509_2B)
"JCOG0509_2B"


#' JCOG0605, figure 2A
#' 
#' Kaplan-Meier digitized data from JCOG0605, figure 2A (PMID 27312053). A reported sample size of 180 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with
#' cisplatin, etoposide, and irinotecan versus topotecan alone as
#' second-line treatment for patients with sensitive relapsed small-cell
#' lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3
#' trial. Lancet Oncol 2016; 17: 1147–57.
#' 
#' @format
#' A data frame of 180 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (combination_chemotherapy, topotecan) \cr
#' }
#' 
#' @usage
#' JCOG0605_2A
#' 
#' @examples
#' summary(JCOG0605_2A)
#' 
#' kmplot(JCOG0605_2A)
"JCOG0605_2A"


#' JCOG0605, figure 2B
#' 
#' Kaplan-Meier digitized data from JCOG0605, figure 2B (PMID 27312053). A reported sample size of 180 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with
#' cisplatin, etoposide, and irinotecan versus topotecan alone as
#' second-line treatment for patients with sensitive relapsed small-cell
#' lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3
#' trial. Lancet Oncol 2016; 17: 1147–57.
#' 
#' @format
#' A data frame of 180 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (combination_chemotherapy, topotecan) \cr
#' }
#' 
#' @usage
#' JCOG0605_2B
#' 
#' @examples
#' summary(JCOG0605_2B)
#' 
#' kmplot(JCOG0605_2B)
"JCOG0605_2B"


#' JFMC33-0502, figure 2A
#' 
#' Kaplan-Meier digitized data from JFMC33-0502, figure 2A (PMID 26347106). A reported sample size of 1,071 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Sadahiro S, Tsuchiya T, Sasaki K, et al. Randomized phase III trial
#' of treatment duration for oral uracil and tegafur plus leucovorin as
#' adjuvant chemotherapy for patients with stage IIB/III colon cancer:
#' final results of JFMC33-0502. Ann Oncol 2015; 26: 2274–80.
#' 
#' @format
#' A data frame of 1,060 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, study) \cr
#' }
#' 
#' @usage
#' `JFMC33-0502_2A`
#' 
#' @examples
#' summary(`JFMC33-0502_2A`)
#' 
#' kmplot(`JFMC33-0502_2A`)
"JFMC33-0502_2A"


#' JFMC33-0502, figure 2B
#' 
#' Kaplan-Meier digitized data from JFMC33-0502, figure 2B (PMID 26347106). A reported sample size of 1,071 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Sadahiro S, Tsuchiya T, Sasaki K, et al. Randomized phase III trial
#' of treatment duration for oral uracil and tegafur plus leucovorin as
#' adjuvant chemotherapy for patients with stage IIB/III colon cancer:
#' final results of JFMC33-0502. Ann Oncol 2015; 26: 2274–80.
#' 
#' @format
#' A data frame of 1,060 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, study) \cr
#' }
#' 
#' @usage
#' `JFMC33-0502_2B`
#' 
#' @examples
#' summary(`JFMC33-0502_2B`)
#' 
#' kmplot(`JFMC33-0502_2B`)
"JFMC33-0502_2B"


#' KEYNOTE024, figure 1A
#' 
#' Kaplan-Meier digitized data from KEYNOTE024, figure 1A (PMID 27718847). A reported sample size of 305 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus
#' Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J
#' Med 2016; 375: 1823–33.
#' 
#' @format
#' A data frame of 305 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, pembrolizumab) \cr
#' }
#' 
#' @usage
#' KEYNOTE024_1A
#' 
#' @examples
#' summary(KEYNOTE024_1A)
#' 
#' kmplot(KEYNOTE024_1A)
"KEYNOTE024_1A"


#' KEYNOTE024, figure 2
#' 
#' Kaplan-Meier digitized data from KEYNOTE024, figure 2 (PMID 27718847). A reported sample size of 305 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus
#' Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J
#' Med 2016; 375: 1823–33.
#' 
#' @format
#' A data frame of 305 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, pembrolizumab) \cr
#' }
#' 
#' @usage
#' KEYNOTE024_2
#' 
#' @examples
#' summary(KEYNOTE024_2)
#' 
#' kmplot(KEYNOTE024_2)
"KEYNOTE024_2"


#' LEA, figure 2A
#' 
#' Kaplan-Meier digitized data from LEA, figure 2A (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating
#' the addition of bevacizumab to endocrine therapy as first-line
#' treatment for advanced breast cancer: the letrozole/fulvestrant and
#' avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52.
#' 
#' @format
#' A data frame of 374 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (et, et_b) \cr
#' }
#' 
#' @usage
#' LEA_2A
#' 
#' @examples
#' summary(LEA_2A)
#' 
#' kmplot(LEA_2A)
"LEA_2A"


#' LEA, figure 2C
#' 
#' Kaplan-Meier digitized data from LEA, figure 2C (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating
#' the addition of bevacizumab to endocrine therapy as first-line
#' treatment for advanced breast cancer: the letrozole/fulvestrant and
#' avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52.
#' 
#' @format
#' A data frame of 374 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (et, et_b) \cr
#' }
#' 
#' @usage
#' LEA_2C
#' 
#' @examples
#' summary(LEA_2C)
#' 
#' kmplot(LEA_2C)
"LEA_2C"


#' LUMELung1, figure 2A
#' 
#' Kaplan-Meier digitized data from LUMELung1, figure 2A (PMID 24411639). A reported sample size of 655 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib
#' versus docetaxel plus placebo in patients with previously treated
#' non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind,
#' randomised controlled trial. Lancet Oncol 2014; 15: 143–55.
#' 
#' @format
#' A data frame of 1,134 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (docetaxel_nintedanib, docetaxel_placebo) \cr
#' }
#' 
#' @usage
#' LUMELung1_2A
#' 
#' @examples
#' summary(LUMELung1_2A)
#' 
#' kmplot(LUMELung1_2A)
"LUMELung1_2A"


#' LUMELung1, figure 3C
#' 
#' Kaplan-Meier digitized data from LUMELung1, figure 3C (PMID 24411639). A reported sample size of 655 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib
#' versus docetaxel plus placebo in patients with previously treated
#' non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind,
#' randomised controlled trial. Lancet Oncol 2014; 15: 143–55.
#' 
#' @format
#' A data frame of 1,314 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (docetaxel_nintedanib, docetaxel_placebo) \cr
#' }
#' 
#' @usage
#' LUMELung1_3C
#' 
#' @examples
#' summary(LUMELung1_3C)
#' 
#' kmplot(LUMELung1_3C)
"LUMELung1_3C"


#' LUXBreast1, figure 2
#' 
#' Kaplan-Meier digitized data from LUXBreast1, figure 2 (PMID 26822398). A reported sample size of 508 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Harbeck N, Huang C-S, Hurvitz S, et al. Afatinib plus vinorelbine
#' versus trastuzumab plus vinorelbine in patients with
#' HER2-overexpressing metastatic breast cancer who had progressed on
#' one previous trastuzumab treatment (LUX-Breast 1): an open-label,
#' randomised, phase 3 trial. Lancet Oncol 2016; 17: 357–66.
#' 
#' @format
#' A data frame of 508 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, t) \cr
#' }
#' 
#' @usage
#' LUXBreast1_2
#' 
#' @examples
#' summary(LUXBreast1_2)
#' 
#' kmplot(LUXBreast1_2)
"LUXBreast1_2"


#' LUXBreast1, figure 4
#' 
#' Kaplan-Meier digitized data from LUXBreast1, figure 4 (PMID 26822398). A reported sample size of 508 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Harbeck N, Huang C-S, Hurvitz S, et al. Afatinib plus vinorelbine
#' versus trastuzumab plus vinorelbine in patients with
#' HER2-overexpressing metastatic breast cancer who had progressed on
#' one previous trastuzumab treatment (LUX-Breast 1): an open-label,
#' randomised, phase 3 trial. Lancet Oncol 2016; 17: 357–66.
#' 
#' @format
#' A data frame of 508 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, t) \cr
#' }
#' 
#' @usage
#' LUXBreast1_4
#' 
#' @examples
#' summary(LUXBreast1_4)
#' 
#' kmplot(LUXBreast1_4)
"LUXBreast1_4"


#' LUXLung3-6, figure 2A
#' 
#' Kaplan-Meier digitized data from LUXLung3-6, figure 2A (PMID 25589191). A reported sample size of 345,364 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based
#' chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung
#' 3 and LUX-Lung 6): analysis of overall survival data from two
#' randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–51.
#' 
#' @format
#' A data frame of 345 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, pemetrexed-cisplatin) \cr
#' }
#' 
#' @usage
#' `LUXLung3-6_2A`
#' 
#' @examples
#' summary(`LUXLung3-6_2A`)
#' 
#' kmplot(`LUXLung3-6_2A`)
"LUXLung3-6_2A"


#' LUXLung3-6, figure 2B
#' 
#' Kaplan-Meier digitized data from LUXLung3-6, figure 2B (PMID 25589191). A reported sample size of 345,364 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based
#' chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung
#' 3 and LUX-Lung 6): analysis of overall survival data from two
#' randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–51.
#' 
#' @format
#' A data frame of 364 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, gemicitabine-cisplatin) \cr
#' }
#' 
#' @usage
#' `LUXLung3-6_2B`
#' 
#' @examples
#' summary(`LUXLung3-6_2B`)
#' 
#' kmplot(`LUXLung3-6_2B`)
"LUXLung3-6_2B"


#' LUXLung5, figure 1A
#' 
#' Kaplan-Meier digitized data from LUXLung5, figure 1A (PMID 26646759). A reported sample size of 220 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Schuler M, Yang JC-H, Park K, et al. Afatinib beyond progression in
#' patients with non-small-cell lung cancer following chemotherapy,
#' erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5
#' trial. Ann Oncol 2016; 27: 417–23.
#' 
#' @format
#' A data frame of 202 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib_paclitaxel, chemo) \cr
#' }
#' 
#' @usage
#' LUXLung5_1A
#' 
#' @examples
#' summary(LUXLung5_1A)
#' 
#' kmplot(LUXLung5_1A)
"LUXLung5_1A"


#' LUXLung5, figure 1B
#' 
#' Kaplan-Meier digitized data from LUXLung5, figure 1B (PMID 26646759). A reported sample size of 220 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Schuler M, Yang JC-H, Park K, et al. Afatinib beyond progression in
#' patients with non-small-cell lung cancer following chemotherapy,
#' erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5
#' trial. Ann Oncol 2016; 27: 417–23.
#' 
#' @format
#' A data frame of 202 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib_paclitaxel, chemo) \cr
#' }
#' 
#' @usage
#' LUXLung5_1B
#' 
#' @examples
#' summary(LUXLung5_1B)
#' 
#' kmplot(LUXLung5_1B)
"LUXLung5_1B"


#' LUXLung6(2), figure 2A
#' 
#' Kaplan-Meier digitized data from LUXLung6(2), figure 2A (PMID 24439929). A reported sample size of 364 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus
#' gemcitabine for first-line treatment of Asian patients with advanced
#' non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an
#' open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213–22.
#' 
#' @format
#' A data frame of 364 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, gemcitabine_cisplatin) \cr
#' }
#' 
#' @usage
#' `LUXLung6(2)_2A`
#' 
#' @examples
#' summary(`LUXLung6(2)_2A`)
#' 
#' kmplot(`LUXLung6(2)_2A`)
"LUXLung6(2)_2A"


#' LUXLung8, figure 2A
#' 
#' Kaplan-Meier digitized data from LUXLung8, figure 2A (PMID 26156651). A reported sample size of 795 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Soria J-C, Felip E, Cobo M, et al. Afatinib versus erlotinib as
#' second-line treatment of patients with advanced squamous cell
#' carcinoma of the lung (LUX-Lung 8): an open-label randomised
#' controlled phase 3 trial. Lancet Oncol 2015; 16: 897–907.
#' 
#' @format
#' A data frame of 795 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, erlotinib) \cr
#' }
#' 
#' @usage
#' LUXLung8_2A
#' 
#' @examples
#' summary(LUXLung8_2A)
#' 
#' kmplot(LUXLung8_2A)
"LUXLung8_2A"


#' LUXLung8, figure 3A
#' 
#' Kaplan-Meier digitized data from LUXLung8, figure 3A (PMID 26156651). A reported sample size of 795 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Soria J-C, Felip E, Cobo M, et al. Afatinib versus erlotinib as
#' second-line treatment of patients with advanced squamous cell
#' carcinoma of the lung (LUX-Lung 8): an open-label randomised
#' controlled phase 3 trial. Lancet Oncol 2015; 16: 897–907.
#' 
#' @format
#' A data frame of 795 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (afatinib, erlotinib) \cr
#' }
#' 
#' @usage
#' LUXLung8_3A
#' 
#' @examples
#' summary(LUXLung8_3A)
#' 
#' kmplot(LUXLung8_3A)
"LUXLung8_3A"


#' MA17R, figure 1A
#' 
#' Kaplan-Meier digitized data from MA17R, figure 1A (PMID 27264120). A reported sample size of 1,918 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor
#' Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209–19.
#' 
#' @format
#' A data frame of 1,918 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, placebo) \cr
#' }
#' 
#' @usage
#' MA17R_1A
#' 
#' @examples
#' summary(MA17R_1A)
#' 
#' kmplot(MA17R_1A)
"MA17R_1A"


#' MA17R, figure 1B
#' 
#' Kaplan-Meier digitized data from MA17R, figure 1B (PMID 27264120). A reported sample size of 1,918 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor
#' Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209–19.
#' 
#' @format
#' A data frame of 1,918 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, placebo) \cr
#' }
#' 
#' @usage
#' MA17R_1B
#' 
#' @examples
#' summary(MA17R_1B)
#' 
#' kmplot(MA17R_1B)
"MA17R_1B"


#' MA31, figure 2
#' 
#' Kaplan-Meier digitized data from MA31, figure 2 (PMID 25779558). A reported sample size of 652 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or Trastuzumab Plus
#' Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive
#' Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol
#' 2015; 33: 1574–83.
#' 
#' @format
#' A data frame of 652 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ltax_l, ttax_t) \cr
#' }
#' 
#' @usage
#' MA31_2
#' 
#' @examples
#' summary(MA31_2)
#' 
#' kmplot(MA31_2)
"MA31_2"


#' MA31, figure 3
#' 
#' Kaplan-Meier digitized data from MA31, figure 3 (PMID 25779558). A reported sample size of 652 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or Trastuzumab Plus
#' Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive
#' Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol
#' 2015; 33: 1574–83.
#' 
#' @format
#' A data frame of 652 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (ltax_l, ttax_t) \cr
#' }
#' 
#' @usage
#' MA31_3
#' 
#' @examples
#' summary(MA31_3)
#' 
#' kmplot(MA31_3)
"MA31_3"


#' MAGRIT, figure 2A
#' 
#' Kaplan-Meier digitized data from MAGRIT, figure 2A (PMID 27132212). A reported sample size of 2,312 for a primary endpoint of DFS(3 primary in diff pop) in lung cancer.
#' 
#' @source
#' Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3
#' cancer immunotherapeutic as adjuvant therapy in patients with
#' resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a
#' randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
#' Oncol 2016; 17: 822–35.
#' 
#' @format
#' A data frame of 2,272 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mage_a3, placebo) \cr
#' }
#' 
#' @usage
#' MAGRIT_2A
#' 
#' @examples
#' summary(MAGRIT_2A)
#' 
#' kmplot(MAGRIT_2A)
"MAGRIT_2A"


#' MAGRIT, figure 2C
#' 
#' Kaplan-Meier digitized data from MAGRIT, figure 2C (PMID 27132212). A reported sample size of 2,312 for a primary endpoint of DFS(3 primary in diff pop) in lung cancer.
#' 
#' @source
#' Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3
#' cancer immunotherapeutic as adjuvant therapy in patients with
#' resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a
#' randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
#' Oncol 2016; 17: 822–35.
#' 
#' @format
#' A data frame of 2,272 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mage_a3, placebo) \cr
#' }
#' 
#' @usage
#' MAGRIT_2C
#' 
#' @examples
#' summary(MAGRIT_2C)
#' 
#' kmplot(MAGRIT_2C)
"MAGRIT_2C"


#' MAINSAIL, figure 2A
#' 
#' Kaplan-Meier digitized data from MAINSAIL, figure 2A (PMID 25743937). A reported sample size of 1,059 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone
#' with or without lenalidomide in chemotherapy-naive patients with
#' metastatic castration-resistant prostate cancer (MAINSAIL): a
#' randomised, double-blind, placebo-controlled phase 3 trial. Lancet
#' Oncol 2015; 16: 417–25.
#' 
#' @format
#' A data frame of 1,059 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lenolidomide, placebo) \cr
#' }
#' 
#' @usage
#' MAINSAIL_2A
#' 
#' @examples
#' summary(MAINSAIL_2A)
#' 
#' kmplot(MAINSAIL_2A)
"MAINSAIL_2A"


#' MAINSAIL, figure 2B
#' 
#' Kaplan-Meier digitized data from MAINSAIL, figure 2B (PMID 25743937). A reported sample size of 1,059 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone
#' with or without lenalidomide in chemotherapy-naive patients with
#' metastatic castration-resistant prostate cancer (MAINSAIL): a
#' randomised, double-blind, placebo-controlled phase 3 trial. Lancet
#' Oncol 2015; 16: 417–25.
#' 
#' @format
#' A data frame of 1,059 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lenolidomide, placebo) \cr
#' }
#' 
#' @usage
#' MAINSAIL_2B
#' 
#' @examples
#' summary(MAINSAIL_2B)
#' 
#' kmplot(MAINSAIL_2B)
"MAINSAIL_2B"


#' MAPS, figure 2A
#' 
#' Kaplan-Meier digitized data from MAPS, figure 2A (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly
#' diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin
#' Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase
#' 3 trial. Lancet 2016; 387: 1405–14.
#' 
#' @format
#' A data frame of 448 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (pc, pcb) \cr
#' }
#' 
#' @usage
#' MAPS_2A
#' 
#' @examples
#' summary(MAPS_2A)
#' 
#' kmplot(MAPS_2A)
"MAPS_2A"


#' MAPS, figure 2C
#' 
#' Kaplan-Meier digitized data from MAPS, figure 2C (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly
#' diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin
#' Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase
#' 3 trial. Lancet 2016; 387: 1405–14.
#' 
#' @format
#' A data frame of 448 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (pc, pcb) \cr
#' }
#' 
#' @usage
#' MAPS_2C
#' 
#' @examples
#' summary(MAPS_2C)
#' 
#' kmplot(MAPS_2C)
"MAPS_2C"


#' MARIANNE(a), figure 2A
#' 
#' Kaplan-Meier digitized data from MARIANNE(a), figure 2A (PMID 28056202). A reported sample size of 1,095 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or
#' Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal
#' Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary
#' Results From the Phase III MARIANNE Study. J Clin Oncol 2017; 35:
#' 141–8.
#' 
#' @format
#' A data frame of 732 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (t-dm1, trastuzumab_taxane) \cr
#' }
#' 
#' @usage
#' `MARIANNE(a)_2A`
#' 
#' @examples
#' summary(`MARIANNE(a)_2A`)
#' 
#' kmplot(`MARIANNE(a)_2A`)
"MARIANNE(a)_2A"


#' MARIANNE(b), figure 2A
#' 
#' Kaplan-Meier digitized data from MARIANNE(b), figure 2A (PMID 28056202). A reported sample size of 1,095 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or
#' Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal
#' Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary
#' Results From the Phase III MARIANNE Study. J Clin Oncol 2017; 35:
#' 141–8.
#' 
#' @format
#' A data frame of 728 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (t-dm1_pertuzumab, trastuzumab_taxane) \cr
#' }
#' 
#' @usage
#' `MARIANNE(b)_2A`
#' 
#' @examples
#' summary(`MARIANNE(b)_2A`)
#' 
#' kmplot(`MARIANNE(b)_2A`)
"MARIANNE(b)_2A"


#' MARQUEE, figure 2A
#' 
#' Kaplan-Meier digitized data from MARQUEE, figure 2A (PMID 26169611). A reported sample size of 1,048 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Scagliotti G, von Pawel J, Novello S, et al. Phase III Multinational,
#' Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ
#' 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated
#' Patients With Locally Advanced or Metastatic Nonsquamous
#' Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2667–74.
#' 
#' @format
#' A data frame of 1,048 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib_placebo, erlotinib_tivantinib) \cr
#' }
#' 
#' @usage
#' MARQUEE_2A
#' 
#' @examples
#' summary(MARQUEE_2A)
#' 
#' kmplot(MARQUEE_2A)
"MARQUEE_2A"


#' MARQUEE, figure 2B
#' 
#' Kaplan-Meier digitized data from MARQUEE, figure 2B (PMID 26169611). A reported sample size of 1,048 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Scagliotti G, von Pawel J, Novello S, et al. Phase III Multinational,
#' Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ
#' 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated
#' Patients With Locally Advanced or Metastatic Nonsquamous
#' Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2667–74.
#' 
#' @format
#' A data frame of 1,048 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib_placebo, erlotinib_tivantinib) \cr
#' }
#' 
#' @usage
#' MARQUEE_2B
#' 
#' @examples
#' summary(MARQUEE_2B)
#' 
#' kmplot(MARQUEE_2B)
"MARQUEE_2B"


#' METlung, figure 2A
#' 
#' Kaplan-Meier digitized data from METlung, figure 2A (PMID 27937096). A reported sample size of 499 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Spigel DR, Edelman MJ, O’Byrne K, et al. Results From the Phase III
#' Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in
#' Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer:
#' METLung. J Clin Oncol 2017; 35: 412–20.
#' 
#' @format
#' A data frame of 499 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (onaturzumab_erlotinib, placebo_erlotinib) \cr
#' }
#' 
#' @usage
#' METlung_2A
#' 
#' @examples
#' summary(METlung_2A)
#' 
#' kmplot(METlung_2A)
"METlung_2A"


#' METlung, figure 3A
#' 
#' Kaplan-Meier digitized data from METlung, figure 3A (PMID 27937096). A reported sample size of 499 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Spigel DR, Edelman MJ, O’Byrne K, et al. Results From the Phase III
#' Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in
#' Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer:
#' METLung. J Clin Oncol 2017; 35: 412–20.
#' 
#' @format
#' A data frame of 499 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (onaturzumab_erlotinib, placebo_erlotinib) \cr
#' }
#' 
#' @usage
#' METlung_3A
#' 
#' @examples
#' summary(METlung_3A)
#' 
#' kmplot(METlung_3A)
"METlung_3A"


#' MINDACT, figure 2C
#' 
#' Kaplan-Meier digitized data from MINDACT, figure 2C (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer.
#' 
#' @source
#' Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an
#' Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med
#' 2016; 375: 717–29.
#' 
#' @format
#' A data frame of 1,497 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr
#' }
#' 
#' @usage
#' MINDACT_2C
#' 
#' @examples
#' summary(MINDACT_2C)
#' 
#' kmplot(MINDACT_2C)
"MINDACT_2C"


#' MINDACT, figure 2D
#' 
#' Kaplan-Meier digitized data from MINDACT, figure 2D (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer.
#' 
#' @source
#' Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an
#' Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med
#' 2016; 375: 717–29.
#' 
#' @format
#' A data frame of 690 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr
#' }
#' 
#' @usage
#' MINDACT_2D
#' 
#' @examples
#' summary(MINDACT_2D)
#' 
#' kmplot(MINDACT_2D)
"MINDACT_2D"


#' MINDACT, figure 2E
#' 
#' Kaplan-Meier digitized data from MINDACT, figure 2E (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer.
#' 
#' @source
#' Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an
#' Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med
#' 2016; 375: 717–29.
#' 
#' @format
#' A data frame of 690 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr
#' }
#' 
#' @usage
#' MINDACT_2E
#' 
#' @examples
#' summary(MINDACT_2E)
#' 
#' kmplot(MINDACT_2E)
"MINDACT_2E"


#' MINDACT, figure 2F
#' 
#' Kaplan-Meier digitized data from MINDACT, figure 2F (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer.
#' 
#' @source
#' Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an
#' Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med
#' 2016; 375: 717–29.
#' 
#' @format
#' A data frame of 690 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr
#' }
#' 
#' @usage
#' MINDACT_2F
#' 
#' @examples
#' summary(MINDACT_2F)
#' 
#' kmplot(MINDACT_2F)
"MINDACT_2F"


#' MIROX, figure 2A
#' 
#' Kaplan-Meier digitized data from MIROX, figure 2A (PMID 25403578). A reported sample size of 284 for a primary endpoint of DFS-2yr in colorectal cancer.
#' 
#' @source
#' Hebbar M, Chibaudel B, André T, et al. FOLFOX4 versus sequential
#' dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable
#' metastatic colorectal cancer (MIROX): a pragmatic approach to
#' chemotherapy timing with perioperative or postoperative chemotherapy
#' from an open-label, randomized phase III trial. Ann Oncol 2015; 26:
#' 340–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfox4, folfox7_folfiri) \cr
#' }
#' 
#' @usage
#' MIROX_2A
#' 
#' @examples
#' summary(MIROX_2A)
#' 
#' kmplot(MIROX_2A)
"MIROX_2A"


#' MIROX, figure 2B
#' 
#' Kaplan-Meier digitized data from MIROX, figure 2B (PMID 25403578). A reported sample size of 284 for a primary endpoint of DFS-2yr in colorectal cancer.
#' 
#' @source
#' Hebbar M, Chibaudel B, André T, et al. FOLFOX4 versus sequential
#' dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable
#' metastatic colorectal cancer (MIROX): a pragmatic approach to
#' chemotherapy timing with perioperative or postoperative chemotherapy
#' from an open-label, randomized phase III trial. Ann Oncol 2015; 26:
#' 340–7.
#' 
#' @format
#' A data frame of 282 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfox4, folfox7_folfiri) \cr
#' }
#' 
#' @usage
#' MIROX_2B
#' 
#' @examples
#' summary(MIROX_2B)
#' 
#' kmplot(MIROX_2B)
"MIROX_2B"


#' MONALEESA2, figure 1
#' 
#' Kaplan-Meier digitized data from MONALEESA2, figure 1 (PMID 27717303). A reported sample size of 668 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line
#' Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016;
#' 375: 1738–48.
#' 
#' @format
#' A data frame of 668 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, ribociclib_letrozole) \cr
#' }
#' 
#' @usage
#' MONALEESA2_1
#' 
#' @examples
#' summary(MONALEESA2_1)
#' 
#' kmplot(MONALEESA2_1)
"MONALEESA2_1"


#' MRC-RT01, figure 2A
#' 
#' Kaplan-Meier digitized data from MRC-RT01, figure 2A (PMID 24581940). A reported sample size of 862 for a primary endpoint of bPFS/OS in prostate cancer.
#' 
#' @source
#' Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus
#' control-dose conformal radiotherapy for prostate cancer: long-term
#' results from the MRC RT01 randomised controlled trial. Lancet Oncol
#' 2014; 15: 464–73.
#' 
#' @format
#' A data frame of 836 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, escalated) \cr
#' }
#' 
#' @usage
#' `MRC-RT01_2A`
#' 
#' @examples
#' summary(`MRC-RT01_2A`)
#' 
#' kmplot(`MRC-RT01_2A`)
"MRC-RT01_2A"


#' MRC-RT01, figure 2C
#' 
#' Kaplan-Meier digitized data from MRC-RT01, figure 2C (PMID 24581940). A reported sample size of 862 for a primary endpoint of bPFS/OS in prostate cancer.
#' 
#' @source
#' Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus
#' control-dose conformal radiotherapy for prostate cancer: long-term
#' results from the MRC RT01 randomised controlled trial. Lancet Oncol
#' 2014; 15: 464–73.
#' 
#' @format
#' A data frame of 835 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, escalated) \cr
#' }
#' 
#' @usage
#' `MRC-RT01_2C`
#' 
#' @examples
#' summary(`MRC-RT01_2C`)
#' 
#' kmplot(`MRC-RT01_2C`)
"MRC-RT01_2C"


#' NCICBR26, figure 2A
#' 
#' Kaplan-Meier digitized data from NCICBR26, figure 2A (PMID 25439692). A reported sample size of 720 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with
#' placebo in pretreated patients with advanced or metastatic
#' non-small-cell lung cancer (NCIC CTG BR.26): a double-blind,
#' randomised, phase 3 trial. Lancet Oncol 2014; 15: 1379–88.
#' 
#' @format
#' A data frame of 720 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (dacomitinib, placebo) \cr
#' }
#' 
#' @usage
#' NCICBR26_2A
#' 
#' @examples
#' summary(NCICBR26_2A)
#' 
#' kmplot(NCICBR26_2A)
"NCICBR26_2A"


#' NCICBR26, figure 2B
#' 
#' Kaplan-Meier digitized data from NCICBR26, figure 2B (PMID 25439692). A reported sample size of 720 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with
#' placebo in pretreated patients with advanced or metastatic
#' non-small-cell lung cancer (NCIC CTG BR.26): a double-blind,
#' randomised, phase 3 trial. Lancet Oncol 2014; 15: 1379–88.
#' 
#' @format
#' A data frame of 720 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (dacomitinib, placebo) \cr
#' }
#' 
#' @usage
#' NCICBR26_2B
#' 
#' @examples
#' summary(NCICBR26_2B)
#' 
#' kmplot(NCICBR26_2B)
"NCICBR26_2B"


#' NCT00294996, figure 1A
#' 
#' Kaplan-Meier digitized data from NCT00294996, figure 1A (PMID 24401928). A reported sample size of 181 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Baselga J, Manikhas A, Cortés J, et al. Phase III trial of
#' nonpegylated liposomal doxorubicin in combination with trastuzumab
#' and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol
#' 2014; 25: 592–8.
#' 
#' @format
#' A data frame of 363 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mpt, pt) \cr
#' }
#' 
#' @usage
#' NCT00294996_1A
#' 
#' @examples
#' summary(NCT00294996_1A)
#' 
#' kmplot(NCT00294996_1A)
"NCT00294996_1A"


#' NCT00294996, figure 1B
#' 
#' Kaplan-Meier digitized data from NCT00294996, figure 1B (PMID 24401928). A reported sample size of 181 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Baselga J, Manikhas A, Cortés J, et al. Phase III trial of
#' nonpegylated liposomal doxorubicin in combination with trastuzumab
#' and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol
#' 2014; 25: 592–8.
#' 
#' @format
#' A data frame of 363 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mpt, pt) \cr
#' }
#' 
#' @usage
#' NCT00294996_1B
#' 
#' @examples
#' summary(NCT00294996_1B)
#' 
#' kmplot(NCT00294996_1B)
"NCT00294996_1B"


#' NCT00337103, figure 2A
#' 
#' Kaplan-Meier digitized data from NCT00337103, figure 2A (PMID 25605862). A reported sample size of 1,102 for a primary endpoint of OS/PFS in breast cancer.
#' 
#' @source
#' Kaufman PA, Awada A, Twelves C, et al. Phase III open-label
#' randomized study of eribulin mesylate versus capecitabine in patients
#' with locally advanced or metastatic breast cancer previously treated
#' with an anthracycline and a taxane. J Clin Oncol 2015; 33: 594–601.
#' 
#' @format
#' A data frame of 1,102 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, eribulin) \cr
#' }
#' 
#' @usage
#' NCT00337103_2A
#' 
#' @examples
#' summary(NCT00337103_2A)
#' 
#' kmplot(NCT00337103_2A)
"NCT00337103_2A"


#' NCT00337103, figure 2B
#' 
#' Kaplan-Meier digitized data from NCT00337103, figure 2B (PMID 25605862). A reported sample size of 1,102 for a primary endpoint of OS/PFS in breast cancer.
#' 
#' @source
#' Kaufman PA, Awada A, Twelves C, et al. Phase III open-label
#' randomized study of eribulin mesylate versus capecitabine in patients
#' with locally advanced or metastatic breast cancer previously treated
#' with an anthracycline and a taxane. J Clin Oncol 2015; 33: 594–601.
#' 
#' @format
#' A data frame of 1,102 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, eribulin) \cr
#' }
#' 
#' @usage
#' NCT00337103_2B
#' 
#' @examples
#' summary(NCT00337103_2B)
#' 
#' kmplot(NCT00337103_2B)
"NCT00337103_2B"


#' NCT00596830, figure 2A
#' 
#' Kaplan-Meier digitized data from NCT00596830, figure 2A (PMID 24888810). A reported sample size of 681 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Langer CJ, Novello S, Park K, et al. Randomized, phase III trial of
#' first-line figitumumab in combination with paclitaxel and carboplatin
#' versus paclitaxel and carboplatin alone in patients with advanced
#' non-small-cell lung cancer. J Clin Oncol 2014; 32: 2059–66.
#' 
#' @format
#' A data frame of 681 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, figitumumab) \cr
#' }
#' 
#' @usage
#' NCT00596830_2A
#' 
#' @examples
#' summary(NCT00596830_2A)
#' 
#' kmplot(NCT00596830_2A)
"NCT00596830_2A"


#' NCT00596830, figure 2B
#' 
#' Kaplan-Meier digitized data from NCT00596830, figure 2B (PMID 24888810). A reported sample size of 681 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Langer CJ, Novello S, Park K, et al. Randomized, phase III trial of
#' first-line figitumumab in combination with paclitaxel and carboplatin
#' versus paclitaxel and carboplatin alone in patients with advanced
#' non-small-cell lung cancer. J Clin Oncol 2014; 32: 2059–66.
#' 
#' @format
#' A data frame of 681 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, figitumumab) \cr
#' }
#' 
#' @usage
#' NCT00596830_2B
#' 
#' @examples
#' summary(NCT00596830_2B)
#' 
#' kmplot(NCT00596830_2B)
"NCT00596830_2B"


#' NCT00614393(a), figure 3A
#' 
#' Kaplan-Meier digitized data from NCT00614393(a), figure 3A (PMID 26405092). A reported sample size of 344 for a primary endpoint of PFS,OS in colorectal cancer.
#' 
#' @source
#' Sclafani F, Kim TY, Cunningham D, et al. A Randomized Phase II/III
#' Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in
#' Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl
#' Cancer Inst 2015; 107: djv258.
#' 
#' @format
#' A data frame of 227 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armc) \cr
#' }
#' 
#' @usage
#' `NCT00614393(a)_3A`
#' 
#' @examples
#' summary(`NCT00614393(a)_3A`)
#' 
#' kmplot(`NCT00614393(a)_3A`)
"NCT00614393(a)_3A"


#' NCT00614393(a), figure 3B
#' 
#' Kaplan-Meier digitized data from NCT00614393(a), figure 3B (PMID 26405092). A reported sample size of 344 for a primary endpoint of PFS,OS in colorectal cancer.
#' 
#' @source
#' Sclafani F, Kim TY, Cunningham D, et al. A Randomized Phase II/III
#' Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in
#' Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl
#' Cancer Inst 2015; 107: djv258.
#' 
#' @format
#' A data frame of 227 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armc) \cr
#' }
#' 
#' @usage
#' `NCT00614393(a)_3B`
#' 
#' @examples
#' summary(`NCT00614393(a)_3B`)
#' 
#' kmplot(`NCT00614393(a)_3B`)
"NCT00614393(a)_3B"


#' NCT00614393(b), figure 3A
#' 
#' Kaplan-Meier digitized data from NCT00614393(b), figure 3A (PMID 26405092). A reported sample size of 344 for a primary endpoint of PFS,OS in colorectal cancer.
#' 
#' @source
#' Sclafani F, Kim TY, Cunningham D, et al. A Randomized Phase II/III
#' Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in
#' Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl
#' Cancer Inst 2015; 107: djv258.
#' 
#' @format
#' A data frame of 228 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (armb, armc) \cr
#' }
#' 
#' @usage
#' `NCT00614393(b)_3A`
#' 
#' @examples
#' summary(`NCT00614393(b)_3A`)
#' 
#' kmplot(`NCT00614393(b)_3A`)
"NCT00614393(b)_3A"


#' NCT00614393(b), figure 3B
#' 
#' Kaplan-Meier digitized data from NCT00614393(b), figure 3B (PMID 26405092). A reported sample size of 344 for a primary endpoint of PFS,OS in colorectal cancer.
#' 
#' @source
#' Sclafani F, Kim TY, Cunningham D, et al. A Randomized Phase II/III
#' Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in
#' Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. J Natl
#' Cancer Inst 2015; 107: djv258.
#' 
#' @format
#' A data frame of 228 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (armb, armc) \cr
#' }
#' 
#' @usage
#' `NCT00614393(b)_3B`
#' 
#' @examples
#' summary(`NCT00614393(b)_3B`)
#' 
#' kmplot(`NCT00614393(b)_3B`)
"NCT00614393(b)_3B"


#' NCT00673049, figure 2A
#' 
#' Kaplan-Meier digitized data from NCT00673049, figure 2A (PMID 25395283). A reported sample size of 583 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase
#' III trial of figitumumab in combination with erlotinib versus
#' erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung
#' cancer. Ann Oncol 2015; 26: 497–504.
#' 
#' @format
#' A data frame of 583 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, figitumumab) \cr
#' }
#' 
#' @usage
#' NCT00673049_2A
#' 
#' @examples
#' summary(NCT00673049_2A)
#' 
#' kmplot(NCT00673049_2A)
"NCT00673049_2A"


#' NCT00673049, figure 2B
#' 
#' Kaplan-Meier digitized data from NCT00673049, figure 2B (PMID 25395283). A reported sample size of 583 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase
#' III trial of figitumumab in combination with erlotinib versus
#' erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung
#' cancer. Ann Oncol 2015; 26: 497–504.
#' 
#' @format
#' A data frame of 583 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, figitumumab) \cr
#' }
#' 
#' @usage
#' NCT00673049_2B
#' 
#' @examples
#' summary(NCT00673049_2B)
#' 
#' kmplot(NCT00673049_2B)
"NCT00673049_2B"


#' NCT00938652, figure 2A
#' 
#' Kaplan-Meier digitized data from NCT00938652, figure 2A (PMID 25349301). A reported sample size of 519 for a primary endpoint of OS/PFS in breast cancer.
#' 
#' @source
#' O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of
#' iniparib plus gemcitabine and carboplatin versus gemcitabine and
#' carboplatin in patients with metastatic triple-negative breast
#' cancer. J Clin Oncol 2014; 32: 3840–7.
#' 
#' @format
#' A data frame of 519 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (gc, gci) \cr
#' }
#' 
#' @usage
#' NCT00938652_2A
#' 
#' @examples
#' summary(NCT00938652_2A)
#' 
#' kmplot(NCT00938652_2A)
"NCT00938652_2A"


#' NCT00938652, figure 2C
#' 
#' Kaplan-Meier digitized data from NCT00938652, figure 2C (PMID 25349301). A reported sample size of 519 for a primary endpoint of OS/PFS in breast cancer.
#' 
#' @source
#' O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of
#' iniparib plus gemcitabine and carboplatin versus gemcitabine and
#' carboplatin in patients with metastatic triple-negative breast
#' cancer. J Clin Oncol 2014; 32: 3840–7.
#' 
#' @format
#' A data frame of 519 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (gc, gci) \cr
#' }
#' 
#' @usage
#' NCT00938652_2C
#' 
#' @examples
#' summary(NCT00938652_2C)
#' 
#' kmplot(NCT00938652_2C)
"NCT00938652_2C"


#' NCT01234311, figure 2A
#' 
#' Kaplan-Meier digitized data from NCT01234311, figure 2A (PMID 27298414). A reported sample size of 1,245 for a primary endpoint of rPFS in prostate cancer.
#' 
#' @source
#' Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind,
#' Placebo-Controlled Phase III Study of Tasquinimod in Men With
#' Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2016;
#' 34: 2636–43.
#' 
#' @format
#' A data frame of 577 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tasq) \cr
#' }
#' 
#' @usage
#' NCT01234311_2A
#' 
#' @examples
#' summary(NCT01234311_2A)
#' 
#' kmplot(NCT01234311_2A)
"NCT01234311_2A"


#' NCT01234311, figure 2B
#' 
#' Kaplan-Meier digitized data from NCT01234311, figure 2B (PMID 27298414). A reported sample size of 1,245 for a primary endpoint of rPFS in prostate cancer.
#' 
#' @source
#' Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind,
#' Placebo-Controlled Phase III Study of Tasquinimod in Men With
#' Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2016;
#' 34: 2636–43.
#' 
#' @format
#' A data frame of 1,158 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tasq) \cr
#' }
#' 
#' @usage
#' NCT01234311_2B
#' 
#' @examples
#' summary(NCT01234311_2B)
#' 
#' kmplot(NCT01234311_2B)
"NCT01234311_2B"


#' NeoALTTO(a), figure 2A
#' 
#' Kaplan-Meier digitized data from NeoALTTO(a), figure 2A (PMID 25130998). A reported sample size of 455 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with
#' trastuzumab for HER2-positive early breast cancer (NeoALTTO):
#' survival outcomes of a randomised, open-label, multicentre, phase 3
#' trial and their association with pathological complete response.
#' Lancet Oncol 2014; 15: 1137–46.
#' 
#' @format
#' A data frame of 303 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, t) \cr
#' }
#' 
#' @usage
#' `NeoALTTO(a)_2A`
#' 
#' @examples
#' summary(`NeoALTTO(a)_2A`)
#' 
#' kmplot(`NeoALTTO(a)_2A`)
"NeoALTTO(a)_2A"


#' NeoALTTO(a), figure 2D
#' 
#' Kaplan-Meier digitized data from NeoALTTO(a), figure 2D (PMID 25130998). A reported sample size of 455 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with
#' trastuzumab for HER2-positive early breast cancer (NeoALTTO):
#' survival outcomes of a randomised, open-label, multicentre, phase 3
#' trial and their association with pathological complete response.
#' Lancet Oncol 2014; 15: 1137–46.
#' 
#' @format
#' A data frame of 303 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (l, t) \cr
#' }
#' 
#' @usage
#' `NeoALTTO(a)_2D`
#' 
#' @examples
#' summary(`NeoALTTO(a)_2D`)
#' 
#' kmplot(`NeoALTTO(a)_2D`)
"NeoALTTO(a)_2D"


#' NeoALTTO(b), figure 2A
#' 
#' Kaplan-Meier digitized data from NeoALTTO(b), figure 2A (PMID 25130998). A reported sample size of 455 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with
#' trastuzumab for HER2-positive early breast cancer (NeoALTTO):
#' survival outcomes of a randomised, open-label, multicentre, phase 3
#' trial and their association with pathological complete response.
#' Lancet Oncol 2014; 15: 1137–46.
#' 
#' @format
#' A data frame of 301 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lapatinib_trastuzumab, t) \cr
#' }
#' 
#' @usage
#' `NeoALTTO(b)_2A`
#' 
#' @examples
#' summary(`NeoALTTO(b)_2A`)
#' 
#' kmplot(`NeoALTTO(b)_2A`)
"NeoALTTO(b)_2A"


#' NeoALTTO(b), figure 2D
#' 
#' Kaplan-Meier digitized data from NeoALTTO(b), figure 2D (PMID 25130998). A reported sample size of 455 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with
#' trastuzumab for HER2-positive early breast cancer (NeoALTTO):
#' survival outcomes of a randomised, open-label, multicentre, phase 3
#' trial and their association with pathological complete response.
#' Lancet Oncol 2014; 15: 1137–46.
#' 
#' @format
#' A data frame of 301 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (lapatinib_trastuzumab, t) \cr
#' }
#' 
#' @usage
#' `NeoALTTO(b)_2D`
#' 
#' @examples
#' summary(`NeoALTTO(b)_2D`)
#' 
#' kmplot(`NeoALTTO(b)_2D`)
"NeoALTTO(b)_2D"


#' NITRO, figure 2A
#' 
#' Kaplan-Meier digitized data from NITRO, figure 2A (PMID 26347110). A reported sample size of 372 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Davidson A, Veillard A-S, Tognela A, et al. A phase III randomized
#' trial of adding topical nitroglycerin to first-line chemotherapy for
#' advanced nonsmall-cell lung cancer: the Australasian lung cancer
#' trials group NITRO trial. Ann Oncol 2015; 26: 2280–6.
#' 
#' @format
#' A data frame of 372 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, nitro_chemo) \cr
#' }
#' 
#' @usage
#' NITRO_2A
#' 
#' @examples
#' summary(NITRO_2A)
#' 
#' kmplot(NITRO_2A)
"NITRO_2A"


#' NITRO, figure 2B
#' 
#' Kaplan-Meier digitized data from NITRO, figure 2B (PMID 26347110). A reported sample size of 372 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Davidson A, Veillard A-S, Tognela A, et al. A phase III randomized
#' trial of adding topical nitroglycerin to first-line chemotherapy for
#' advanced nonsmall-cell lung cancer: the Australasian lung cancer
#' trials group NITRO trial. Ann Oncol 2015; 26: 2280–6.
#' 
#' @format
#' A data frame of 372 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, nitro_chemo) \cr
#' }
#' 
#' @usage
#' NITRO_2B
#' 
#' @examples
#' summary(NITRO_2B)
#' 
#' kmplot(NITRO_2B)
"NITRO_2B"


#' NO16968, figure 2A
#' 
#' Kaplan-Meier digitized data from NO16968, figure 2A (PMID 26324362). A reported sample size of 1,886 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Schmoll H-J, Tabernero J, Maroun J, et al. Capecitabine Plus
#' Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant
#' Therapy for Stage III Colon Cancer: Final Results of the NO16968
#' Randomized Controlled Phase III Trial. J Clin Oncol 2015; 33:
#' 3733–40.
#' 
#' @format
#' A data frame of 1,886 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (fu_fa, xelox) \cr
#' }
#' 
#' @usage
#' NO16968_2A
#' 
#' @examples
#' summary(NO16968_2A)
#' 
#' kmplot(NO16968_2A)
"NO16968_2A"


#' NO16968, figure 2C
#' 
#' Kaplan-Meier digitized data from NO16968, figure 2C (PMID 26324362). A reported sample size of 1,886 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Schmoll H-J, Tabernero J, Maroun J, et al. Capecitabine Plus
#' Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant
#' Therapy for Stage III Colon Cancer: Final Results of the NO16968
#' Randomized Controlled Phase III Trial. J Clin Oncol 2015; 33:
#' 3733–40.
#' 
#' @format
#' A data frame of 1,886 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (fu_fa, xelox) \cr
#' }
#' 
#' @usage
#' NO16968_2C
#' 
#' @examples
#' summary(NO16968_2C)
#' 
#' kmplot(NO16968_2C)
"NO16968_2C"


#' NOAH, figure 2A
#' 
#' Kaplan-Meier digitized data from NOAH, figure 2A (PMID 24657003). A reported sample size of 235 for a primary endpoint of EFS in breast cancer.
#' 
#' @source
#' Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant
#' trastuzumab in patients with HER2-positive locally advanced breast
#' cancer (NOAH): follow-up of a randomised controlled superiority trial
#' with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640–7.
#' 
#' @format
#' A data frame of 235 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, chemotherapy_trastuzumab) \cr
#' }
#' 
#' @usage
#' NOAH_2A
#' 
#' @examples
#' summary(NOAH_2A)
#' 
#' kmplot(NOAH_2A)
"NOAH_2A"


#' NOAH, figure 2B
#' 
#' Kaplan-Meier digitized data from NOAH, figure 2B (PMID 24657003). A reported sample size of 235 for a primary endpoint of EFS in breast cancer.
#' 
#' @source
#' Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant
#' trastuzumab in patients with HER2-positive locally advanced breast
#' cancer (NOAH): follow-up of a randomised controlled superiority trial
#' with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640–7.
#' 
#' @format
#' A data frame of 235 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, chemotherapy_trastuzumab) \cr
#' }
#' 
#' @usage
#' NOAH_2B
#' 
#' @examples
#' summary(NOAH_2B)
#' 
#' kmplot(NOAH_2B)
"NOAH_2B"


#' NSABPB35, figure 2
#' 
#' Kaplan-Meier digitized data from NSABPB35, figure 2 (PMID 26686957). A reported sample size of 3,104 for a primary endpoint of BCFS in breast cancer.
#' 
#' @source
#' Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus
#' tamoxifen in postmenopausal women with ductal carcinoma in situ
#' undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised,
#' double-blind, phase 3 clinical trial. Lancet 2016; 387: 849–56.
#' 
#' @format
#' A data frame of 3,077 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (anastrazole, tamoxifen) \cr
#' }
#' 
#' @usage
#' NSABPB35_2
#' 
#' @examples
#' summary(NSABPB35_2)
#' 
#' kmplot(NSABPB35_2)
"NSABPB35_2"


#' NSABPB35, figure 3
#' 
#' Kaplan-Meier digitized data from NSABPB35, figure 3 (PMID 26686957). A reported sample size of 3,104 for a primary endpoint of BCFS in breast cancer.
#' 
#' @source
#' Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus
#' tamoxifen in postmenopausal women with ductal carcinoma in situ
#' undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised,
#' double-blind, phase 3 clinical trial. Lancet 2016; 387: 849–56.
#' 
#' @format
#' A data frame of 3,077 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (anastrazole, tamoxifen) \cr
#' }
#' 
#' @usage
#' NSABPB35_3
#' 
#' @examples
#' summary(NSABPB35_3)
#' 
#' kmplot(NSABPB35_3)
"NSABPB35_3"


#' NSABPB40, figure 3A
#' 
#' Kaplan-Meier digitized data from NSABPB40, figure 3A (PMID 26272770). A reported sample size of 1,206 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant
#' bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]):
#' secondary outcomes of a phase 3, randomised controlled trial. Lancet
#' Oncol 2015; 16: 1037–48.
#' 
#' @format
#' A data frame of 1,184 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, no_bev) \cr
#' }
#' 
#' @usage
#' NSABPB40_3A
#' 
#' @examples
#' summary(NSABPB40_3A)
#' 
#' kmplot(NSABPB40_3A)
"NSABPB40_3A"


#' NSABPB40, figure 3B
#' 
#' Kaplan-Meier digitized data from NSABPB40, figure 3B (PMID 26272770). A reported sample size of 1,206 for a primary endpoint of pCR in breast cancer.
#' 
#' @source
#' Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant
#' bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]):
#' secondary outcomes of a phase 3, randomised controlled trial. Lancet
#' Oncol 2015; 16: 1037–48.
#' 
#' @format
#' A data frame of 1,186 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, no_bev) \cr
#' }
#' 
#' @usage
#' NSABPB40_3B
#' 
#' @examples
#' summary(NSABPB40_3B)
#' 
#' kmplot(NSABPB40_3B)
"NSABPB40_3B"


#' NSABPR04, figure 3A
#' 
#' Kaplan-Meier digitized data from NSABPR04, figure 3A (PMID 26374429). A reported sample size of 1,608 for a primary endpoint of Local-regional tumor control in colorectal cancer.
#' 
#' @source
#' Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or
#' Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal
#' Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer
#' Inst 2015; 107. DOI:10.1093/jnci/djv248.
#' 
#' @format
#' A data frame of 1,567 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab LRR event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu, cape) \cr
#' }
#' 
#' @usage
#' NSABPR04_3A
#' 
#' @examples
#' summary(NSABPR04_3A)
#' 
#' kmplot(NSABPR04_3A)
"NSABPR04_3A"


#' NSABPR04, figure 3B
#' 
#' Kaplan-Meier digitized data from NSABPR04, figure 3B (PMID 26374429). A reported sample size of 1,608 for a primary endpoint of Local-regional tumor control in colorectal cancer.
#' 
#' @source
#' Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or
#' Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal
#' Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer
#' Inst 2015; 107. DOI:10.1093/jnci/djv248.
#' 
#' @format
#' A data frame of 1,284 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab LRR event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (no_oxali, oxali) \cr
#' }
#' 
#' @usage
#' NSABPR04_3B
#' 
#' @examples
#' summary(NSABPR04_3B)
#' 
#' kmplot(NSABPR04_3B)
"NSABPR04_3B"


#' NSABPR04, figure 5A
#' 
#' Kaplan-Meier digitized data from NSABPR04, figure 5A (PMID 26374429). A reported sample size of 1,608 for a primary endpoint of Local-regional tumor control in colorectal cancer.
#' 
#' @source
#' Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or
#' Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal
#' Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer
#' Inst 2015; 107. DOI:10.1093/jnci/djv248.
#' 
#' @format
#' A data frame of 1,567 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fu, cape) \cr
#' }
#' 
#' @usage
#' NSABPR04_5A
#' 
#' @examples
#' summary(NSABPR04_5A)
#' 
#' kmplot(NSABPR04_5A)
"NSABPR04_5A"


#' NSABPR04, figure 5B
#' 
#' Kaplan-Meier digitized data from NSABPR04, figure 5B (PMID 26374429). A reported sample size of 1,608 for a primary endpoint of Local-regional tumor control in colorectal cancer.
#' 
#' @source
#' Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or
#' Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal
#' Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer
#' Inst 2015; 107. DOI:10.1093/jnci/djv248.
#' 
#' @format
#' A data frame of 1,284 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (no_oxali, oxali) \cr
#' }
#' 
#' @usage
#' NSABPR04_5B
#' 
#' @examples
#' summary(NSABPR04_5B)
#' 
#' kmplot(NSABPR04_5B)
"NSABPR04_5B"


#' NTR1527, figure 2
#' 
#' Kaplan-Meier digitized data from NTR1527, figure 2 (PMID 25230595). A reported sample size of 498 for a primary endpoint of OS-1yr in lung cancer.
#' 
#' @source
#' Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic
#' radiotherapy for extensive stage small-cell lung cancer: a phase 3
#' randomised controlled trial. Lancet 2015; 385: 36–42.
#' 
#' @format
#' A data frame of 495 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, thoracic rt) \cr
#' }
#' 
#' @usage
#' NTR1527_2
#' 
#' @examples
#' summary(NTR1527_2)
#' 
#' kmplot(NTR1527_2)
"NTR1527_2"


#' NTR1527, figure 4
#' 
#' Kaplan-Meier digitized data from NTR1527, figure 4 (PMID 25230595). A reported sample size of 498 for a primary endpoint of OS-1yr in lung cancer.
#' 
#' @source
#' Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic
#' radiotherapy for extensive stage small-cell lung cancer: a phase 3
#' randomised controlled trial. Lancet 2015; 385: 36–42.
#' 
#' @format
#' A data frame of 495 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, thoracic rt) \cr
#' }
#' 
#' @usage
#' NTR1527_4
#' 
#' @examples
#' summary(NTR1527_4)
#' 
#' kmplot(NTR1527_4)
"NTR1527_4"


#' OMEGA, figure 3A
#' 
#' Kaplan-Meier digitized data from OMEGA, figure 3A (PMID 24504445). A reported sample size of 78 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, et al. A randomized
#' phase III study comparing pegylated liposomal doxorubicin with
#' capecitabine as first-line chemotherapy in elderly patients with
#' metastatic breast cancer: results of the OMEGA study of the Dutch
#' Breast Cancer Research Group BOOG. Ann Oncol 2014; 25: 599–605.
#' 
#' @format
#' A data frame of 78 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, peg_doxorubicin) \cr
#' }
#' 
#' @usage
#' OMEGA_3A
#' 
#' @examples
#' summary(OMEGA_3A)
#' 
#' kmplot(OMEGA_3A)
"OMEGA_3A"


#' OMEGA, figure 3B
#' 
#' Kaplan-Meier digitized data from OMEGA, figure 3B (PMID 24504445). A reported sample size of 78 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, et al. A randomized
#' phase III study comparing pegylated liposomal doxorubicin with
#' capecitabine as first-line chemotherapy in elderly patients with
#' metastatic breast cancer: results of the OMEGA study of the Dutch
#' Breast Cancer Research Group BOOG. Ann Oncol 2014; 25: 599–605.
#' 
#' @format
#' A data frame of 78 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, peg_doxorubicin) \cr
#' }
#' 
#' @usage
#' OMEGA_3B
#' 
#' @examples
#' summary(OMEGA_3B)
#' 
#' kmplot(OMEGA_3B)
"OMEGA_3B"


#' OPTIMAL, figure 1
#' 
#' Kaplan-Meier digitized data from OPTIMAL, figure 1 (PMID 26141208). A reported sample size of 165 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Zhou C, Wu YL, Chen G, et al. Final overall survival results from a
#' randomised, phase III study of erlotinib versus chemotherapy as
#' first-line treatment of EGFR mutation-positive advanced
#' non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26:
#' 1877–83.
#' 
#' @format
#' A data frame of 154 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, gem_carboplatin) \cr
#' }
#' 
#' @usage
#' OPTIMAL_1
#' 
#' @examples
#' summary(OPTIMAL_1)
#' 
#' kmplot(OPTIMAL_1)
"OPTIMAL_1"


#' OPTIMOX3, figure 3A
#' 
#' Kaplan-Meier digitized data from OPTIMOX3, figure 3A (PMID 26474518). A reported sample size of 700 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or
#' without erlotinib as maintenance therapy in patients with metastatic
#' colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label,
#' phase 3 trial. Lancet Oncol 2015; 16: 1493–505.
#' 
#' @format
#' A data frame of 452 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, bev_erlotinib) \cr
#' }
#' 
#' @usage
#' OPTIMOX3_3A
#' 
#' @examples
#' summary(OPTIMOX3_3A)
#' 
#' kmplot(OPTIMOX3_3A)
"OPTIMOX3_3A"


#' OPTIMOX3, figure 3B
#' 
#' Kaplan-Meier digitized data from OPTIMOX3, figure 3B (PMID 26474518). A reported sample size of 700 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or
#' without erlotinib as maintenance therapy in patients with metastatic
#' colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label,
#' phase 3 trial. Lancet Oncol 2015; 16: 1493–505.
#' 
#' @format
#' A data frame of 452 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, bev_erlotinib) \cr
#' }
#' 
#' @usage
#' OPTIMOX3_3B
#' 
#' @examples
#' summary(OPTIMOX3_3B)
#' 
#' kmplot(OPTIMOX3_3B)
"OPTIMOX3_3B"


#' PALOMA2, figure 1A
#' 
#' Kaplan-Meier digitized data from PALOMA2, figure 1A (PMID 27959613). A reported sample size of 666 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in
#' Advanced Breast Cancer. N Engl J Med 2016; 375: 1925–36.
#' 
#' @format
#' A data frame of 666 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (palbociclib_letrozole, placebo_letrozole) \cr
#' }
#' 
#' @usage
#' PALOMA2_1A
#' 
#' @examples
#' summary(PALOMA2_1A)
#' 
#' kmplot(PALOMA2_1A)
"PALOMA2_1A"


#' PALOMA3, figure 1A
#' 
#' Kaplan-Meier digitized data from PALOMA3, figure 1A (PMID 26030518). A reported sample size of 521 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Turner NC, Ro J, André F, et al. Palbociclib in
#' Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015;
#' 373: 209–19.
#' 
#' @format
#' A data frame of 521 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (palbociclib_fulvestrant, placebo_fulvestrant) \cr
#' }
#' 
#' @usage
#' PALOMA3_1A
#' 
#' @examples
#' summary(PALOMA3_1A)
#' 
#' kmplot(PALOMA3_1A)
"PALOMA3_1A"


#' PALOMA3, figure 2A
#' 
#' Kaplan-Meier digitized data from PALOMA3, figure 2A (PMID 26947331). A reported sample size of 521 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus
#' palbociclib versus fulvestrant plus placebo for treatment of
#' hormone-receptor-positive, HER2-negative metastatic breast cancer
#' that progressed on previous endocrine therapy (PALOMA-3): final
#' analysis of the multicentre, double-blind, phase 3 randomised
#' controlled trial. Lancet Oncol 2016; 17: 425–39.
#' 
#' @format
#' A data frame of 521 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (fulvestrant_palbociclib, fulvestrant_placebo) \cr
#' }
#' 
#' @usage
#' PALOMA3_2A
#' 
#' @examples
#' summary(PALOMA3_2A)
#' 
#' kmplot(PALOMA3_2A)
"PALOMA3_2A"


#' PEGASE07, figure 2A
#' 
#' Kaplan-Meier digitized data from PEGASE07, figure 2A (PMID 25943350). A reported sample size of 174 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Gonçalves A, Pierga J-Y, Ferrero J-M, et al. UNICANCER-PEGASE 07
#' study: a randomized phase III trial evaluating postoperative
#' docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for
#' treatment of inflammatory breast cancer. Ann Oncol 2015; 26: 1692–7.
#' 
#' @format
#' A data frame of 174 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armb) \cr
#' }
#' 
#' @usage
#' PEGASE07_2A
#' 
#' @examples
#' summary(PEGASE07_2A)
#' 
#' kmplot(PEGASE07_2A)
"PEGASE07_2A"


#' PEGASE07, figure 2B
#' 
#' Kaplan-Meier digitized data from PEGASE07, figure 2B (PMID 25943350). A reported sample size of 174 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Gonçalves A, Pierga J-Y, Ferrero J-M, et al. UNICANCER-PEGASE 07
#' study: a randomized phase III trial evaluating postoperative
#' docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for
#' treatment of inflammatory breast cancer. Ann Oncol 2015; 26: 1692–7.
#' 
#' @format
#' A data frame of 174 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (arma, armb) \cr
#' }
#' 
#' @usage
#' PEGASE07_2B
#' 
#' @examples
#' summary(PEGASE07_2B)
#' 
#' kmplot(PEGASE07_2B)
"PEGASE07_2B"


#' PETACC8, figure 2A
#' 
#' Kaplan-Meier digitized data from PETACC8, figure 2A (PMID 24928083). A reported sample size of 2,559 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and
#' leucovorin with or without cetuximab in patients with resected stage
#' III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
#' Lancet Oncol 2014; 15: 862–73.
#' 
#' @format
#' A data frame of 1,602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfox4, folfox4_cetuximab) \cr
#' }
#' 
#' @usage
#' PETACC8_2A
#' 
#' @examples
#' summary(PETACC8_2A)
#' 
#' kmplot(PETACC8_2A)
"PETACC8_2A"


#' PETACC8, figure 3A
#' 
#' Kaplan-Meier digitized data from PETACC8, figure 3A (PMID 24928083). A reported sample size of 2,559 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and
#' leucovorin with or without cetuximab in patients with resected stage
#' III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
#' Lancet Oncol 2014; 15: 862–73.
#' 
#' @format
#' A data frame of 1,602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfox4, folfox4_cetuximab) \cr
#' }
#' 
#' @usage
#' PETACC8_3A
#' 
#' @examples
#' summary(PETACC8_3A)
#' 
#' kmplot(PETACC8_3A)
"PETACC8_3A"


#' PREVAIL, figure 1A
#' 
#' Kaplan-Meier digitized data from PREVAIL, figure 1A (PMID 24881730). A reported sample size of 1,717 for a primary endpoint of PFS/OS in prostate cancer.
#' 
#' @source
#' Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic
#' prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33.
#' 
#' @format
#' A data frame of 1,633 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab RPFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (enzalutamide, placebo) \cr
#' }
#' 
#' @usage
#' PREVAIL_1A
#' 
#' @examples
#' summary(PREVAIL_1A)
#' 
#' kmplot(PREVAIL_1A)
"PREVAIL_1A"


#' PREVAIL, figure 1B
#' 
#' Kaplan-Meier digitized data from PREVAIL, figure 1B (PMID 24881730). A reported sample size of 1,717 for a primary endpoint of PFS/OS in prostate cancer.
#' 
#' @source
#' Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic
#' prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33.
#' 
#' @format
#' A data frame of 1,717 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (enzalutamide, placebo) \cr
#' }
#' 
#' @usage
#' PREVAIL_1B
#' 
#' @examples
#' summary(PREVAIL_1B)
#' 
#' kmplot(PREVAIL_1B)
"PREVAIL_1B"


#' PROCLAIM, figure 2A
#' 
#' Kaplan-Meier digitized data from PROCLAIM, figure 2A (PMID 26811519). A reported sample size of 598 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Senan S, Brade A, Wang L-H, et al. PROCLAIM: Randomized Phase III
#' Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic
#' Radiation Therapy Followed by Consolidation Chemotherapy in Locally
#' Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016;
#' 34: 953–62.
#' 
#' @format
#' A data frame of 598 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (eto_cis, pem_cis) \cr
#' }
#' 
#' @usage
#' PROCLAIM_2A
#' 
#' @examples
#' summary(PROCLAIM_2A)
#' 
#' kmplot(PROCLAIM_2A)
"PROCLAIM_2A"


#' PROCLAIM, figure 2B
#' 
#' Kaplan-Meier digitized data from PROCLAIM, figure 2B (PMID 26811519). A reported sample size of 598 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Senan S, Brade A, Wang L-H, et al. PROCLAIM: Randomized Phase III
#' Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic
#' Radiation Therapy Followed by Consolidation Chemotherapy in Locally
#' Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016;
#' 34: 953–62.
#' 
#' @format
#' A data frame of 598 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (eto_cis, pem_cis) \cr
#' }
#' 
#' @usage
#' PROCLAIM_2B
#' 
#' @examples
#' summary(PROCLAIM_2B)
#' 
#' kmplot(PROCLAIM_2B)
"PROCLAIM_2B"


#' PROCTOR-SCRIPT, figure 1A
#' 
#' Kaplan-Meier digitized data from PROCTOR-SCRIPT, figure 1A (PMID 25480874). A reported sample size of 437 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Breugom AJ, van Gijn W, Muller EW, et al. Adjuvant chemotherapy for
#' rectal cancer patients treated with preoperative (chemo)radiotherapy
#' and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG)
#' randomized phase III trial. Ann Oncol 2015; 26: 696–701.
#' 
#' @format
#' A data frame of 437 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, observation) \cr
#' }
#' 
#' @usage
#' `PROCTOR-SCRIPT_1A`
#' 
#' @examples
#' summary(`PROCTOR-SCRIPT_1A`)
#' 
#' kmplot(`PROCTOR-SCRIPT_1A`)
"PROCTOR-SCRIPT_1A"


#' PROCTOR-SCRIPT, figure 1B
#' 
#' Kaplan-Meier digitized data from PROCTOR-SCRIPT, figure 1B (PMID 25480874). A reported sample size of 437 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Breugom AJ, van Gijn W, Muller EW, et al. Adjuvant chemotherapy for
#' rectal cancer patients treated with preoperative (chemo)radiotherapy
#' and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG)
#' randomized phase III trial. Ann Oncol 2015; 26: 696–701.
#' 
#' @format
#' A data frame of 437 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, observation) \cr
#' }
#' 
#' @usage
#' `PROCTOR-SCRIPT_1B`
#' 
#' @examples
#' summary(`PROCTOR-SCRIPT_1B`)
#' 
#' kmplot(`PROCTOR-SCRIPT_1B`)
"PROCTOR-SCRIPT_1B"


#' PROFILE1014, figure 1A
#' 
#' Kaplan-Meier digitized data from PROFILE1014, figure 1A (PMID 25470694). A reported sample size of 343 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus
#' chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:
#' 2167–77.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, crizotinib) \cr
#' }
#' 
#' @usage
#' PROFILE1014_1A
#' 
#' @examples
#' summary(PROFILE1014_1A)
#' 
#' kmplot(PROFILE1014_1A)
"PROFILE1014_1A"


#' PROFILE1014, figure 1B
#' 
#' Kaplan-Meier digitized data from PROFILE1014, figure 1B (PMID 25470694). A reported sample size of 343 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus
#' chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371:
#' 2167–77.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, crizotinib) \cr
#' }
#' 
#' @usage
#' PROFILE1014_1B
#' 
#' @examples
#' summary(PROFILE1014_1B)
#' 
#' kmplot(PROFILE1014_1B)
"PROFILE1014_1B"


#' PROFILE1014, figure 2A
#' 
#' Kaplan-Meier digitized data from PROFILE1014, figure 2A (PMID 27022118). A reported sample size of 343 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial Efficacy of
#' Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive
#' Non–Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol
#' 2016; 34: 2858-67.
#' 
#' @format
#' A data frame of 343 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, crizotinib) \cr
#' }
#' 
#' @usage
#' PROFILE1014_2A
#' 
#' @examples
#' summary(PROFILE1014_2A)
#' 
#' kmplot(PROFILE1014_2A)
"PROFILE1014_2A"


#' PROSE, figure 2A
#' 
#' Kaplan-Meier digitized data from PROSE, figure 2A (PMID 24831979). A reported sample size of 142 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Gregorc V, Novello S, Lazzari C, et al. Predictive value of a
#' proteomic signature in patients with non-small-cell lung cancer
#' treated with second-line erlotinib or chemotherapy (PROSE): a
#' biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014;
#' 15: 713–21.
#' 
#' @format
#' A data frame of 263 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, erlotinib) \cr
#' }
#' 
#' @usage
#' PROSE_2A
#' 
#' @examples
#' summary(PROSE_2A)
#' 
#' kmplot(PROSE_2A)
"PROSE_2A"


#' PROSE, figure 2B
#' 
#' Kaplan-Meier digitized data from PROSE, figure 2B (PMID 24831979). A reported sample size of 142 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Gregorc V, Novello S, Lazzari C, et al. Predictive value of a
#' proteomic signature in patients with non-small-cell lung cancer
#' treated with second-line erlotinib or chemotherapy (PROSE): a
#' biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014;
#' 15: 713–21.
#' 
#' @format
#' A data frame of 263 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo, erlotinib) \cr
#' }
#' 
#' @usage
#' PROSE_2B
#' 
#' @examples
#' summary(PROSE_2B)
#' 
#' kmplot(PROSE_2B)
"PROSE_2B"


#' QUARTZ, figure 2A
#' 
#' Kaplan-Meier digitized data from QUARTZ, figure 2A (PMID 27604504). A reported sample size of 538 for a primary endpoint of QALYs in lung cancer.
#' 
#' @source
#' Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and
#' supportive care with or without whole brain radiotherapy in treating
#' patients with non-small cell lung cancer with brain metastases
#' unsuitable for resection or stereotactic radiotherapy (QUARTZ):
#' results from a phase 3, non-inferiority, randomised trial. Lancet
#' 2016; 388: 2004–14.
#' 
#' @format
#' A data frame of 538 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in weeks) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (osc, osc_wbrt) \cr
#' }
#' 
#' @usage
#' QUARTZ_2A
#' 
#' @examples
#' summary(QUARTZ_2A)
#' 
#' kmplot(QUARTZ_2A)
"QUARTZ_2A"


#' QUASAR2, figure 2A
#' 
#' Kaplan-Meier digitized data from QUASAR2, figure 2A (PMID 27660192). A reported sample size of 1,952 for a primary endpoint of DFS3 in colorectal cancer.
#' 
#' @source
#' Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus
#' bevacizumab versus capecitabine alone in patients with colorectal
#' cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet
#' Oncol 2016; 17: 1543–57.
#' 
#' @format
#' A data frame of 1,933 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, cap_bev) \cr
#' }
#' 
#' @usage
#' QUASAR2_2A
#' 
#' @examples
#' summary(QUASAR2_2A)
#' 
#' kmplot(QUASAR2_2A)
"QUASAR2_2A"


#' QUASAR2, figure 2B
#' 
#' Kaplan-Meier digitized data from QUASAR2, figure 2B (PMID 27660192). A reported sample size of 1,952 for a primary endpoint of DFS3 in colorectal cancer.
#' 
#' @source
#' Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus
#' bevacizumab versus capecitabine alone in patients with colorectal
#' cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet
#' Oncol 2016; 17: 1543–57.
#' 
#' @format
#' A data frame of 1,939 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cap, cap_bev) \cr
#' }
#' 
#' @usage
#' QUASAR2_2B
#' 
#' @examples
#' summary(QUASAR2_2B)
#' 
#' kmplot(QUASAR2_2B)
"QUASAR2_2B"


#' R98, figure 2
#' 
#' Kaplan-Meier digitized data from R98, figure 2 (PMID 25739671). A reported sample size of 357 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Delbaldo C, Ychou M, Zawadi A, et al. Postoperative irinotecan in
#' resected stage II-III rectal cancer: final analysis of the French R98
#' Intergroup trial†. Ann Oncol 2015; 26: 1208–15.
#' 
#' @format
#' A data frame of 357 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fulv, 5fulv_cpt11) \cr
#' }
#' 
#' @usage
#' R98_2
#' 
#' @examples
#' summary(R98_2)
#' 
#' kmplot(R98_2)
"R98_2"


#' R98, figure 4
#' 
#' Kaplan-Meier digitized data from R98, figure 4 (PMID 25739671). A reported sample size of 357 for a primary endpoint of DFS in colorectal cancer.
#' 
#' @source
#' Delbaldo C, Ychou M, Zawadi A, et al. Postoperative irinotecan in
#' resected stage II-III rectal cancer: final analysis of the French R98
#' Intergroup trial†. Ann Oncol 2015; 26: 1208–15.
#' 
#' @format
#' A data frame of 357 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (5fulv, 5fulv_cpt11) \cr
#' }
#' 
#' @usage
#' R98_4
#' 
#' @examples
#' summary(R98_4)
#' 
#' kmplot(R98_4)
"R98_4"


#' RADIANT, figure 2A
#' 
#' Kaplan-Meier digitized data from RADIANT, figure 2A (PMID 26324372). A reported sample size of 973 for a primary endpoint of DFS in lung cancer.
#' 
#' @source
#' Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant Erlotinib Versus
#' Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer
#' (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol
#' 2015; 33: 4007–14.
#' 
#' @format
#' A data frame of 973 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, placebo) \cr
#' }
#' 
#' @usage
#' RADIANT_2A
#' 
#' @examples
#' summary(RADIANT_2A)
#' 
#' kmplot(RADIANT_2A)
"RADIANT_2A"


#' RADIANT4, figure 2A
#' 
#' Kaplan-Meier digitized data from RADIANT4, figure 2A (PMID 26703889). A reported sample size of 302 for a primary endpoint of PFS in lung/colorectal cancer.
#' 
#' @source
#' Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of
#' advanced, non-functional neuroendocrine tumours of the lung or
#' gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled,
#' phase 3 study. Lancet 2016; 387: 968–77.
#' 
#' @format
#' A data frame of 302 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (everolimus, placebo) \cr
#' }
#' 
#' @usage
#' RADIANT4_2A
#' 
#' @examples
#' summary(RADIANT4_2A)
#' 
#' kmplot(RADIANT4_2A)
"RADIANT4_2A"


#' RADIANT4, figure 2C
#' 
#' Kaplan-Meier digitized data from RADIANT4, figure 2C (PMID 26703889). A reported sample size of 302 for a primary endpoint of PFS in lung/colorectal cancer.
#' 
#' @source
#' Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of
#' advanced, non-functional neuroendocrine tumours of the lung or
#' gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled,
#' phase 3 study. Lancet 2016; 387: 968–77.
#' 
#' @format
#' A data frame of 302 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (everolimus, placebo) \cr
#' }
#' 
#' @usage
#' RADIANT4_2C
#' 
#' @examples
#' summary(RADIANT4_2C)
#' 
#' kmplot(RADIANT4_2C)
"RADIANT4_2C"


#' RAISE, figure 2A
#' 
#' Kaplan-Meier digitized data from RAISE, figure 2A (PMID 25877855). A reported sample size of 1,072 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in
#' combination with second-line FOLFIRI in patients with metastatic
#' colorectal carcinoma that progressed during or after first-line
#' therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
#' (RAISE): a randomised, double-blind, multicentre, phase 3 study.
#' Lancet Oncol 2015; 16: 499–508.
#' 
#' @format
#' A data frame of 1,072 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo_folfiri, ramucirumab_folfiri) \cr
#' }
#' 
#' @usage
#' RAISE_2A
#' 
#' @examples
#' summary(RAISE_2A)
#' 
#' kmplot(RAISE_2A)
"RAISE_2A"


#' RAISE, figure 2B
#' 
#' Kaplan-Meier digitized data from RAISE, figure 2B (PMID 25877855). A reported sample size of 1,072 for a primary endpoint of OS in colorectal cancer.
#' 
#' @source
#' Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in
#' combination with second-line FOLFIRI in patients with metastatic
#' colorectal carcinoma that progressed during or after first-line
#' therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
#' (RAISE): a randomised, double-blind, multicentre, phase 3 study.
#' Lancet Oncol 2015; 16: 499–508.
#' 
#' @format
#' A data frame of 1,072 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo_folfiri, ramucirumab_folfiri) \cr
#' }
#' 
#' @usage
#' RAISE_2B
#' 
#' @examples
#' summary(RAISE_2B)
#' 
#' kmplot(RAISE_2B)
"RAISE_2B"


#' RECOURSE, figure 1A
#' 
#' Kaplan-Meier digitized data from RECOURSE, figure 1A (PMID 25970050). A reported sample size of 800 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102
#' for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:
#' 1909–19.
#' 
#' @format
#' A data frame of 800 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tas-102) \cr
#' }
#' 
#' @usage
#' RECOURSE_1A
#' 
#' @examples
#' summary(RECOURSE_1A)
#' 
#' kmplot(RECOURSE_1A)
"RECOURSE_1A"


#' RECOURSE, figure 2A
#' 
#' Kaplan-Meier digitized data from RECOURSE, figure 2A (PMID 25970050). A reported sample size of 800 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102
#' for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:
#' 1909–19.
#' 
#' @format
#' A data frame of 800 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, tas102) \cr
#' }
#' 
#' @usage
#' RECOURSE_2A
#' 
#' @examples
#' summary(RECOURSE_2A)
#' 
#' kmplot(RECOURSE_2A)
"RECOURSE_2A"


#' REVEL, figure 2
#' 
#' Kaplan-Meier digitized data from REVEL, figure 2 (PMID 24933332). A reported sample size of 1,825 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel
#' versus placebo plus docetaxel for second-line treatment of stage IV
#' non-small-cell lung cancer after disease progression on
#' platinum-based therapy (REVEL): a multicentre, double-blind,
#' randomised phase 3 trial. Lancet 2014; 384: 665–73.
#' 
#' @format
#' A data frame of 1,253 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo_docetaxel, ramucirumab_docetaxel) \cr
#' }
#' 
#' @usage
#' REVEL_2
#' 
#' @examples
#' summary(REVEL_2)
#' 
#' kmplot(REVEL_2)
"REVEL_2"


#' REVEL, figure 3
#' 
#' Kaplan-Meier digitized data from REVEL, figure 3 (PMID 24933332). A reported sample size of 1,825 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel
#' versus placebo plus docetaxel for second-line treatment of stage IV
#' non-small-cell lung cancer after disease progression on
#' platinum-based therapy (REVEL): a multicentre, double-blind,
#' randomised phase 3 trial. Lancet 2014; 384: 665–73.
#' 
#' @format
#' A data frame of 1,253 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo_docetaxel, ramucirumab_docetaxel) \cr
#' }
#' 
#' @usage
#' REVEL_3
#' 
#' @examples
#' summary(REVEL_3)
#' 
#' kmplot(REVEL_3)
"REVEL_3"


#' ROSE, figure 2A
#' 
#' Kaplan-Meier digitized data from ROSE, figure 2A (PMID 25185099). A reported sample size of 1,144 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of
#' ROSE/TRIO-12, a randomized placebo-controlled phase III trial
#' evaluating the addition of ramucirumab to first-line docetaxel
#' chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33:
#' 141–8.
#' 
#' @format
#' A data frame of 1,144 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (pbo_doc, ram_doc) \cr
#' }
#' 
#' @usage
#' ROSE_2A
#' 
#' @examples
#' summary(ROSE_2A)
#' 
#' kmplot(ROSE_2A)
"ROSE_2A"


#' ROSE, figure 2C
#' 
#' Kaplan-Meier digitized data from ROSE, figure 2C (PMID 25185099). A reported sample size of 1,144 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of
#' ROSE/TRIO-12, a randomized placebo-controlled phase III trial
#' evaluating the addition of ramucirumab to first-line docetaxel
#' chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33:
#' 141–8.
#' 
#' @format
#' A data frame of 1,144 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (pbo_doc, ram_doc) \cr
#' }
#' 
#' @usage
#' ROSE_2C
#' 
#' @examples
#' summary(ROSE_2C)
#' 
#' kmplot(ROSE_2C)
"ROSE_2C"


#' RTOG0415, figure 2
#' 
#' Kaplan-Meier digitized data from RTOG0415, figure 2 (PMID 27044935). A reported sample size of 1,115 for a primary endpoint of DFS in prostate cancer.
#' 
#' @source
#' Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III
#' Noninferiority Study Comparing Two Radiotherapy Fractionation
#' Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol
#' 2016; 34: 2325–32.
#' 
#' @format
#' A data frame of 1,092 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (70gy, 73.8gy) \cr
#' }
#' 
#' @usage
#' RTOG0415_2
#' 
#' @examples
#' summary(RTOG0415_2)
#' 
#' kmplot(RTOG0415_2)
"RTOG0415_2"


#' RTOG0617, figure 2A
#' 
#' Kaplan-Meier digitized data from RTOG0617, figure 2A (PMID 25601342). A reported sample size of 166 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose
#' conformal radiotherapy with concurrent and consolidation carboplatin
#' plus paclitaxel with or without cetuximab for patients with stage
#' IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised,
#' two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187–99.
#' 
#' @format
#' A data frame of 424 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (60gy, 74gy) \cr
#' }
#' 
#' @usage
#' RTOG0617_2A
#' 
#' @examples
#' summary(RTOG0617_2A)
#' 
#' kmplot(RTOG0617_2A)
"RTOG0617_2A"


#' RTOG0617, figure 2B
#' 
#' Kaplan-Meier digitized data from RTOG0617, figure 2B (PMID 25601342). A reported sample size of 166 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose
#' conformal radiotherapy with concurrent and consolidation carboplatin
#' plus paclitaxel with or without cetuximab for patients with stage
#' IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised,
#' two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187–99.
#' 
#' @format
#' A data frame of 465 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cetuximab, no_cetuximab) \cr
#' }
#' 
#' @usage
#' RTOG0617_2B
#' 
#' @examples
#' summary(RTOG0617_2B)
#' 
#' kmplot(RTOG0617_2B)
"RTOG0617_2B"


#' RTOG9804, figure 2C
#' 
#' Kaplan-Meier digitized data from RTOG9804, figure 2C (PMID 25605856). A reported sample size of 632 for a primary endpoint of ILF in breast cancer.
#' 
#' @source
#' McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective
#' randomized trial for good-risk ductal carcinoma in situ comparing
#' radiotherapy with observation. J Clin Oncol 2015; 33: 709–15.
#' 
#' @format
#' A data frame of 585 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (observation, rt) \cr
#' }
#' 
#' @usage
#' RTOG9804_2C
#' 
#' @examples
#' summary(RTOG9804_2C)
#' 
#' kmplot(RTOG9804_2C)
"RTOG9804_2C"


#' RTOG9804, figure 2D
#' 
#' Kaplan-Meier digitized data from RTOG9804, figure 2D (PMID 25605856). A reported sample size of 632 for a primary endpoint of ILF in breast cancer.
#' 
#' @source
#' McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective
#' randomized trial for good-risk ductal carcinoma in situ comparing
#' radiotherapy with observation. J Clin Oncol 2015; 33: 709–15.
#' 
#' @format
#' A data frame of 585 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (observation, rt) \cr
#' }
#' 
#' @usage
#' RTOG9804_2D
#' 
#' @examples
#' summary(RTOG9804_2D)
#' 
#' kmplot(RTOG9804_2D)
"RTOG9804_2D"


#' SAKK, figure 2A
#' 
#' Kaplan-Meier digitized data from SAKK, figure 2A (PMID 26275735). A reported sample size of 232 for a primary endpoint of EFS in lung cancer.
#' 
#' @source
#' Pless M, Stupp R, Ris H-B, et al. Induction chemoradiation in stage
#' IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
#' Lancet 2015; 386: 1049–56.
#' 
#' @format
#' A data frame of 232 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo_surgery, crt_surgery) \cr
#' }
#' 
#' @usage
#' SAKK_2A
#' 
#' @examples
#' summary(SAKK_2A)
#' 
#' kmplot(SAKK_2A)
"SAKK_2A"


#' SAKK, figure 2B
#' 
#' Kaplan-Meier digitized data from SAKK, figure 2B (PMID 26275735). A reported sample size of 232 for a primary endpoint of EFS in lung cancer.
#' 
#' @source
#' Pless M, Stupp R, Ris H-B, et al. Induction chemoradiation in stage
#' IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
#' Lancet 2015; 386: 1049–56.
#' 
#' @format
#' A data frame of 232 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chemo_surgery, crt_surgery) \cr
#' }
#' 
#' @usage
#' SAKK_2B
#' 
#' @examples
#' summary(SAKK_2B)
#' 
#' kmplot(SAKK_2B)
"SAKK_2B"


#' SAKK4106, figure 1
#' 
#' Kaplan-Meier digitized data from SAKK4106, figure 1 (PMID 25605741). A reported sample size of 262 for a primary endpoint of TTP in colorectal cancer.
#' 
#' @source
#' Koeberle D, Betticher DC, von Moos R, et al. Bevacizumab continuation
#' versus no continuation after first-line chemotherapy plus bevacizumab
#' in patients with metastatic colorectal cancer: a randomized phase III
#' non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26: 709–14.
#' 
#' @format
#' A data frame of 262 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, no_bev) \cr
#' }
#' 
#' @usage
#' SAKK4106_1
#' 
#' @examples
#' summary(SAKK4106_1)
#' 
#' kmplot(SAKK4106_1)
"SAKK4106_1"


#' SAKK4106, figure 3
#' 
#' Kaplan-Meier digitized data from SAKK4106, figure 3 (PMID 25605741). A reported sample size of 262 for a primary endpoint of TTP in colorectal cancer.
#' 
#' @source
#' Koeberle D, Betticher DC, von Moos R, et al. Bevacizumab continuation
#' versus no continuation after first-line chemotherapy plus bevacizumab
#' in patients with metastatic colorectal cancer: a randomized phase III
#' non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26: 709–14.
#' 
#' @format
#' A data frame of 262 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev, no_bev) \cr
#' }
#' 
#' @usage
#' SAKK4106_3
#' 
#' @examples
#' summary(SAKK4106_3)
#' 
#' kmplot(SAKK4106_3)
"SAKK4106_3"


#' SELECTBC, figure 2A
#' 
#' Kaplan-Meier digitized data from SELECTBC, figure 2A (PMID 26617202). A reported sample size of 618 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the
#' first-line chemotherapy for metastatic breast cancer (SELECT BC): an
#' open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol
#' 2016; 17: 90–8.
#' 
#' @format
#' A data frame of 592 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (s_1, taxane) \cr
#' }
#' 
#' @usage
#' SELECTBC_2A
#' 
#' @examples
#' summary(SELECTBC_2A)
#' 
#' kmplot(SELECTBC_2A)
"SELECTBC_2A"


#' SELECTBC, figure 2B
#' 
#' Kaplan-Meier digitized data from SELECTBC, figure 2B (PMID 26617202). A reported sample size of 618 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the
#' first-line chemotherapy for metastatic breast cancer (SELECT BC): an
#' open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol
#' 2016; 17: 90–8.
#' 
#' @format
#' A data frame of 592 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab TTF event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (s1, taxane) \cr
#' }
#' 
#' @usage
#' SELECTBC_2B
#' 
#' @examples
#' summary(SELECTBC_2B)
#' 
#' kmplot(SELECTBC_2B)
"SELECTBC_2B"


#' SIRFLOX, figure 3
#' 
#' Kaplan-Meier digitized data from SIRFLOX, figure 3 (PMID 26903575). A reported sample size of 530 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized
#' Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus
#' Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus
#' Selective Internal Radiation Therapy in Patients With Metastatic
#' Colorectal Cancer. J Clin Oncol 2016; 34: 1723–31.
#' 
#' @format
#' A data frame of 530 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (mfolfox6, mfolfox6_rt) \cr
#' }
#' 
#' @usage
#' SIRFLOX_3
#' 
#' @examples
#' summary(SIRFLOX_3)
#' 
#' kmplot(SIRFLOX_3)
"SIRFLOX_3"


#' SMART, figure 3
#' 
#' Kaplan-Meier digitized data from SMART, figure 3 (PMID 27345639). A reported sample size of 203 for a primary endpoint of PTM-incidence in lung cancer.
#' 
#' @source
#' Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for
#' the prevention of procedure-tract metastases after surgical and
#' large-bore pleural procedures in malignant pleural mesothelioma
#' (SMART): a multicentre, open-label, phase 3, randomised controlled
#' trial. Lancet Oncol 2016; 17: 1094–104.
#' 
#' @format
#' A data frame of 203 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in days) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (deferred_rt, immediate_rt) \cr
#' }
#' 
#' @usage
#' SMART_3
#' 
#' @examples
#' summary(SMART_3)
#' 
#' kmplot(SMART_3)
"SMART_3"


#' SMX1132531, figure 1
#' 
#' Kaplan-Meier digitized data from SMX1132531, figure 1 (PMID 25538174). A reported sample size of 105 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Lim SH, Lee JY, Lee M-Y, et al. A randomized phase III trial of
#' stereotactic radiosurgery (SRS) versus observation for patients with
#' asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.
#' Ann Oncol 2015; 26: 762–8.
#' 
#' @format
#' A data frame of 98 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (srs, upfront_chemotherapy) \cr
#' }
#' 
#' @usage
#' SMX1132531_1
#' 
#' @examples
#' summary(SMX1132531_1)
#' 
#' kmplot(SMX1132531_1)
"SMX1132531_1"


#' SOFT, figure 2A
#' 
#' Kaplan-Meier digitized data from SOFT, figure 2A (PMID 25495490). A reported sample size of 3,066 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression
#' in premenopausal breast cancer. N Engl J Med 2015; 372: 436–46.
#' 
#' @format
#' A data frame of 2,033 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (tamoxifen, tamoxifen_os) \cr
#' }
#' 
#' @usage
#' SOFT_2A
#' 
#' @examples
#' summary(SOFT_2A)
#' 
#' kmplot(SOFT_2A)
"SOFT_2A"


#' SQUIRE, figure 2A
#' 
#' Kaplan-Meier digitized data from SQUIRE, figure 2A (PMID 26045340). A reported sample size of 1,093 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine
#' and cisplatin versus gemcitabine and cisplatin alone as first-line
#' therapy in patients with stage IV squamous non-small-cell lung cancer
#' (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet
#' Oncol 2015; 16: 763–74.
#' 
#' @format
#' A data frame of 1,093 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (gem_cis, necitumumab_gem_cis) \cr
#' }
#' 
#' @usage
#' SQUIRE_2A
#' 
#' @examples
#' summary(SQUIRE_2A)
#' 
#' kmplot(SQUIRE_2A)
"SQUIRE_2A"


#' SQUIRE, figure 2B
#' 
#' Kaplan-Meier digitized data from SQUIRE, figure 2B (PMID 26045340). A reported sample size of 1,093 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine
#' and cisplatin versus gemcitabine and cisplatin alone as first-line
#' therapy in patients with stage IV squamous non-small-cell lung cancer
#' (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet
#' Oncol 2015; 16: 763–74.
#' 
#' @format
#' A data frame of 1,093 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (gem_cis, necitumumab_gem_cis) \cr
#' }
#' 
#' @usage
#' SQUIRE_2B
#' 
#' @examples
#' summary(SQUIRE_2B)
#' 
#' kmplot(SQUIRE_2B)
"SQUIRE_2B"


#' TANIA, figure 2
#' 
#' Kaplan-Meier digitized data from TANIA, figure 2 (PMID 25273342). A reported sample size of 494 for a primary endpoint of PFS in breast cancer.
#' 
#' @source
#' von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus
#' chemotherapy versus chemotherapy alone as second-line treatment for
#' patients with HER2-negative locally recurrent or metastatic breast
#' cancer after first-line treatment with bevacizumab plus chemotherapy
#' (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014;
#' 15: 1269–78.
#' 
#' @format
#' A data frame of 494 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (chem_bev, chemo) \cr
#' }
#' 
#' @usage
#' TANIA_2
#' 
#' @examples
#' summary(TANIA_2)
#' 
#' kmplot(TANIA_2)
"TANIA_2"


#' TCOG0701, figure 1A
#' 
#' Kaplan-Meier digitized data from TCOG0701, figure 1A (PMID 25908605). A reported sample size of 608 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of
#' oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese
#' patients with advanced non-small-cell lung cancer: TCOG0701 CATS
#' trial. Ann Oncol 2015; 26: 1401–8.
#' 
#' @format
#' A data frame of 596 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (docetaxel_cis, s1_cis) \cr
#' }
#' 
#' @usage
#' TCOG0701_1A
#' 
#' @examples
#' summary(TCOG0701_1A)
#' 
#' kmplot(TCOG0701_1A)
"TCOG0701_1A"


#' TCOG0701, figure 1B
#' 
#' Kaplan-Meier digitized data from TCOG0701, figure 1B (PMID 25908605). A reported sample size of 608 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of
#' oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese
#' patients with advanced non-small-cell lung cancer: TCOG0701 CATS
#' trial. Ann Oncol 2015; 26: 1401–8.
#' 
#' @format
#' A data frame of 596 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (docetaxel_cis, s1_cis) \cr
#' }
#' 
#' @usage
#' TCOG0701_1B
#' 
#' @examples
#' summary(TCOG0701_1B)
#' 
#' kmplot(TCOG0701_1B)
"TCOG0701_1B"


#' TEXT-SOFT(2), figure 2A
#' 
#' Kaplan-Meier digitized data from TEXT-SOFT(2), figure 2A (PMID 24881463). A reported sample size of 4,690 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with
#' ovarian suppression in premenopausal breast cancer. N Engl J Med
#' 2014; 371: 107–18.
#' 
#' @format
#' A data frame of 4,690 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (exemestane_os, tamoxifen_os) \cr
#' }
#' 
#' @usage
#' `TEXT-SOFT(2)_2A`
#' 
#' @examples
#' summary(`TEXT-SOFT(2)_2A`)
#' 
#' kmplot(`TEXT-SOFT(2)_2A`)
"TEXT-SOFT(2)_2A"


#' TEXT-SOFT(2), figure 2D
#' 
#' Kaplan-Meier digitized data from TEXT-SOFT(2), figure 2D (PMID 24881463). A reported sample size of 4,690 for a primary endpoint of DFS in breast cancer.
#' 
#' @source
#' Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with
#' ovarian suppression in premenopausal breast cancer. N Engl J Med
#' 2014; 371: 107–18.
#' 
#' @format
#' A data frame of 4,690 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (exemestane_os, tamoxifen_os) \cr
#' }
#' 
#' @usage
#' `TEXT-SOFT(2)_2D`
#' 
#' @examples
#' summary(`TEXT-SOFT(2)_2D`)
#' 
#' kmplot(`TEXT-SOFT(2)_2D`)
"TEXT-SOFT(2)_2D"


#' TH3RESA, figure 2A
#' 
#' Kaplan-Meier digitized data from TH3RESA, figure 2A (PMID 24793816). A reported sample size of 602 for a primary endpoint of PFS/OS in breast cancer.
#' 
#' @source
#' Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine
#' versus treatment of physician’s choice for pretreated HER2-positive
#' advanced breast cancer (TH3RESA): a randomised, open-label, phase 3
#' trial. Lancet Oncol 2014; 15: 689–99.
#' 
#' @format
#' A data frame of 602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (physicians_choice, trastuzumab_emtansine) \cr
#' }
#' 
#' @usage
#' TH3RESA_2A
#' 
#' @examples
#' summary(TH3RESA_2A)
#' 
#' kmplot(TH3RESA_2A)
"TH3RESA_2A"


#' TH3RESA, figure 4
#' 
#' Kaplan-Meier digitized data from TH3RESA, figure 4 (PMID 24793816). A reported sample size of 602 for a primary endpoint of PFS/OS in breast cancer.
#' 
#' @source
#' Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine
#' versus treatment of physician’s choice for pretreated HER2-positive
#' advanced breast cancer (TH3RESA): a randomised, open-label, phase 3
#' trial. Lancet Oncol 2014; 15: 689–99.
#' 
#' @format
#' A data frame of 602 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (physicians_choice, trastuzumab_emtansine) \cr
#' }
#' 
#' @usage
#' TH3RESA_4
#' 
#' @examples
#' summary(TH3RESA_4)
#' 
#' kmplot(TH3RESA_4)
"TH3RESA_4"


#' TRAPEZE, figure 1A
#' 
#' Kaplan-Meier digitized data from TRAPEZE, figure 1A (PMID 26794729). A reported sample size of 757 for a primary endpoint of cPFS,cost-effectiveness in prostate cancer.
#' 
#' @source
#' James ND, Pirrie SJ, Pope AM, et al. Clinical Outcomes and Survival
#' Following Treatment of Metastatic Castrate-Refractory Prostate Cancer
#' With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both:
#' The TRAPEZE Randomized Clinical Trial. JAMA Oncol 2016; 2: 493–9.
#' 
#' @format
#' A data frame of 757 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (no_za, za) \cr
#' }
#' 
#' @usage
#' TRAPEZE_1A
#' 
#' @examples
#' summary(TRAPEZE_1A)
#' 
#' kmplot(TRAPEZE_1A)
"TRAPEZE_1A"


#' TRAPEZE, figure 1B
#' 
#' Kaplan-Meier digitized data from TRAPEZE, figure 1B (PMID 26794729). A reported sample size of 757 for a primary endpoint of cPFS,cost-effectiveness in prostate cancer.
#' 
#' @source
#' James ND, Pirrie SJ, Pope AM, et al. Clinical Outcomes and Survival
#' Following Treatment of Metastatic Castrate-Refractory Prostate Cancer
#' With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both:
#' The TRAPEZE Randomized Clinical Trial. JAMA Oncol 2016; 2: 493–9.
#' 
#' @format
#' A data frame of 757 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (no_sr89, sr89) \cr
#' }
#' 
#' @usage
#' TRAPEZE_1B
#' 
#' @examples
#' summary(TRAPEZE_1B)
#' 
#' kmplot(TRAPEZE_1B)
"TRAPEZE_1B"


#' TRIBE, figure 2
#' 
#' Kaplan-Meier digitized data from TRIBE, figure 2 (PMID 26338525). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus
#' bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment
#' of patients with metastatic colorectal cancer: updated overall
#' survival and molecular subgroup analyses of the open-label, phase 3
#' TRIBE study. Lancet Oncol 2015; 16: 1306–15.
#' 
#' @format
#' A data frame of 508 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri_bev, folfoxiri_bev) \cr
#' }
#' 
#' @usage
#' TRIBE_2
#' 
#' @examples
#' summary(TRIBE_2)
#' 
#' kmplot(TRIBE_2)
"TRIBE_2"


#' TRIBE(2), figure 2A
#' 
#' Kaplan-Meier digitized data from TRIBE(2), figure 2A (PMID 25970050). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102
#' for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:
#' 1909–19.
#' 
#' @format
#' A data frame of 508 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfoxiri_bevacizumab) \cr
#' }
#' 
#' @usage
#' `TRIBE(2)_2A`
#' 
#' @examples
#' summary(`TRIBE(2)_2A`)
#' 
#' kmplot(`TRIBE(2)_2A`)
"TRIBE(2)_2A"


#' TRIBE(2), figure 2B
#' 
#' Kaplan-Meier digitized data from TRIBE(2), figure 2B (PMID 25337750). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer.
#' 
#' @source
#' Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with
#' FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. N Engl J
#' Med 2014; 371: 1609-18.
#' 
#' @format
#' A data frame of 508 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfoxiri_bevacizumab) \cr
#' }
#' 
#' @usage
#' `TRIBE(2)_2B`
#' 
#' @examples
#' summary(`TRIBE(2)_2B`)
#' 
#' kmplot(`TRIBE(2)_2B`)
"TRIBE(2)_2B"


#' TROG0306, figure 2
#' 
#' Kaplan-Meier digitized data from TROG0306, figure 2 (PMID 27155740). A reported sample size of 293 for a primary endpoint of OS in prostate cancer.
#' 
#' @source
#' Duchesne GM, Woo HH, Bassett JK, et al. Timing of
#' androgen-deprivation therapy in patients with prostate cancer with a
#' rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised,
#' multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17:
#' 727–37.
#' 
#' @format
#' A data frame of 293 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in years) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (delayed_adt, immediate_adt) \cr
#' }
#' 
#' @usage
#' TROG0306_2
#' 
#' @examples
#' summary(TROG0306_2)
#' 
#' kmplot(TROG0306_2)
"TROG0306_2"


#' TURANDOT, figure 2B
#' 
#' Kaplan-Meier digitized data from TURANDOT, figure 2B (PMID 27501767). A reported sample size of 564 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Zielinski C, Láng I, Inbar M, et al. Bevacizumab plus paclitaxel
#' versus bevacizumab plus capecitabine as first-line treatment for
#' HER2-negative metastatic breast cancer (TURANDOT): primary endpoint
#' results of a randomised, open-label, non-inferiority, phase 3 trial.
#' Lancet Oncol 2016; 17: 1230–9.
#' 
#' @format
#' A data frame of 564 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_capecitabine, bev_paclitaxel) \cr
#' }
#' 
#' @usage
#' TURANDOT_2B
#' 
#' @examples
#' summary(TURANDOT_2B)
#' 
#' kmplot(TURANDOT_2B)
"TURANDOT_2B"


#' TURANDOT, figure 3
#' 
#' Kaplan-Meier digitized data from TURANDOT, figure 3 (PMID 27501767). A reported sample size of 564 for a primary endpoint of OS in breast cancer.
#' 
#' @source
#' Zielinski C, Láng I, Inbar M, et al. Bevacizumab plus paclitaxel
#' versus bevacizumab plus capecitabine as first-line treatment for
#' HER2-negative metastatic breast cancer (TURANDOT): primary endpoint
#' results of a randomised, open-label, non-inferiority, phase 3 trial.
#' Lancet Oncol 2016; 17: 1230–9.
#' 
#' @format
#' A data frame of 564 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (bev_capecitabine, bev_paclitaxel) \cr
#' }
#' 
#' @usage
#' TURANDOT_3
#' 
#' @examples
#' summary(TURANDOT_3)
#' 
#' kmplot(TURANDOT_3)
"TURANDOT_3"


#' VANTAGE014, figure 2
#' 
#' Kaplan-Meier digitized data from VANTAGE014, figure 2 (PMID 25800891). A reported sample size of 661 for a primary endpoint of OS/safety in lung cancer.
#' 
#' @source
#' Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with
#' advanced malignant pleural mesothelioma who have progressed on
#' previous chemotherapy (VANTAGE-014): a phase 3, double-blind,
#' randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 447–56.
#' 
#' @format
#' A data frame of 661 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in weeks) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, vorinostat) \cr
#' }
#' 
#' @usage
#' VANTAGE014_2
#' 
#' @examples
#' summary(VANTAGE014_2)
#' 
#' kmplot(VANTAGE014_2)
"VANTAGE014_2"


#' VANTAGE014, figure 4
#' 
#' Kaplan-Meier digitized data from VANTAGE014, figure 4 (PMID 25800891). A reported sample size of 661 for a primary endpoint of OS/safety in lung cancer.
#' 
#' @source
#' Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with
#' advanced malignant pleural mesothelioma who have progressed on
#' previous chemotherapy (VANTAGE-014): a phase 3, double-blind,
#' randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 447–56.
#' 
#' @format
#' A data frame of 661 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in weeks) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (placebo, vorinostat) \cr
#' }
#' 
#' @usage
#' VANTAGE014_4
#' 
#' @examples
#' summary(VANTAGE014_4)
#' 
#' kmplot(VANTAGE014_4)
"VANTAGE014_4"


#' WJOG5108L, figure 2A
#' 
#' Kaplan-Meier digitized data from WJOG5108L, figure 2A (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study
#' Comparing Gefitinib With Erlotinib in Patients With Previously
#' Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016;
#' 34: 3248–57.
#' 
#' @format
#' A data frame of 559 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, gefitinib) \cr
#' }
#' 
#' @usage
#' WJOG5108L_2A
#' 
#' @examples
#' summary(WJOG5108L_2A)
#' 
#' kmplot(WJOG5108L_2A)
"WJOG5108L_2A"


#' WJOG5108L, figure 2B
#' 
#' Kaplan-Meier digitized data from WJOG5108L, figure 2B (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer.
#' 
#' @source
#' Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study
#' Comparing Gefitinib With Erlotinib in Patients With Previously
#' Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016;
#' 34: 3248–57.
#' 
#' @format
#' A data frame of 559 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (erlotinib, gefitinib) \cr
#' }
#' 
#' @usage
#' WJOG5108L_2B
#' 
#' @examples
#' summary(WJOG5108L_2B)
#' 
#' kmplot(WJOG5108L_2B)
"WJOG5108L_2B"


#' WJOG5208L, figure 2A
#' 
#' Kaplan-Meier digitized data from WJOG5208L, figure 2A (PMID 26522337). A reported sample size of 355 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel
#' versus cisplatin plus docetaxel for advanced or relapsed squamous
#' cell carcinoma of the lung (WJOG5208L): a randomised, open-label,
#' phase 3 trial. Lancet Oncol 2015; 16: 1630–8.
#' 
#' @format
#' A data frame of 349 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin_docetaxel, nedaplatin_docetaxel) \cr
#' }
#' 
#' @usage
#' WJOG5208L_2A
#' 
#' @examples
#' summary(WJOG5208L_2A)
#' 
#' kmplot(WJOG5208L_2A)
"WJOG5208L_2A"


#' WJOG5208L, figure 2B
#' 
#' Kaplan-Meier digitized data from WJOG5208L, figure 2B (PMID 26522337). A reported sample size of 355 for a primary endpoint of OS in lung cancer.
#' 
#' @source
#' Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel
#' versus cisplatin plus docetaxel for advanced or relapsed squamous
#' cell carcinoma of the lung (WJOG5208L): a randomised, open-label,
#' phase 3 trial. Lancet Oncol 2015; 16: 1630–8.
#' 
#' @format
#' A data frame of 349 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (cisplatin_docetaxel, nedaplatin_docetaxel) \cr
#' }
#' 
#' @usage
#' WJOG5208L_2B
#' 
#' @examples
#' summary(WJOG5208L_2B)
#' 
#' kmplot(WJOG5208L_2B)
"WJOG5208L_2B"


#' WSG-ARA, figure 3
#' 
#' Kaplan-Meier digitized data from WSG-ARA, figure 3 (PMID 24356620). A reported sample size of 1,234 for a primary endpoint of EFS in breast cancer.
#' 
#' @source
#' Nitz U, Gluz O, Zuna I, et al. Final results from the prospective
#' phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on
#' event-free survival in early breast cancer. Ann Oncol 2014; 25:
#' 75–80.
#' 
#' @format
#' A data frame of 1,170 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (da_negative, da_positive) \cr
#' }
#' 
#' @usage
#' `WSG-ARA_3`
#' 
#' @examples
#' summary(`WSG-ARA_3`)
#' 
#' kmplot(`WSG-ARA_3`)
"WSG-ARA_3"


#' WSGAGO, figure 2A
#' 
#' Kaplan-Meier digitized data from WSGAGO, figure 2A (PMID 24827128). A reported sample size of 2,011 for a primary endpoint of EFS in breast cancer.
#' 
#' @source
#' Nitz U, Gluz O, Huober J, et al. Final analysis of the prospective
#' WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1)
#' early breast cancer: efficacy and predictive value of Ki67
#' expression. Ann Oncol 2014; 25: 1551–7.
#' 
#' @format
#' A data frame of 1,930 observations and 3 variables:
#' \tabular{lll}{
#' \tab \code{time} \tab event time (in months) \cr
#' \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr
#' \tab \code{arm} \tab treatment arms (control, ed_doc) \cr
#' }
#' 
#' @usage
#' WSGAGO_2A
#' 
#' @examples
#' summary(WSGAGO_2A)
#' 
#' kmplot(WSGAGO_2A)
"WSGAGO_2A"


